BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Mass-tag technology responding to intracellular signals as a novel assay system for the diagnosis of tumor.

A novel mass spectrometry-based assay system for determining protein kinase activity employing mass-tagged substrate peptide probes was used for the diagnosis of tumors.

The phosphorylation ratio for the reaction of the H-type peptide probe with the tumor tissue lysate (B16 melanoma) was more than three times higher than that of the D type peptide probe with the normal skin tissue lysate.

These results show that the novel assay system for detecting protein kinase activity using mass-tag technology can be a simple and useful means to profile protein kinase activity for cell or tissue lysate samples, and can be applied to the diagnosis of tumors.

[MeSH-major] Melanoma, Experimental / diagnosis. Peptides / chemistry. Protein Kinases / analysis. Skin Neoplasms / diagnosis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Am Soc Mass Spectrom. 2005 Apr;16(4):482-90 [15792717.001]

[Cites] Crit Rev Oncog. 1994;5(5):429-50 [8519807.001]

[Cites] Curr Opin Cell Biol. 1997 Apr;9(2):161-7 [9069266.001]

[Cites] Biochem J. 1992 Apr 1;283 ( Pt 1):159-64 [1567363.001]

[Cites] Endocr Relat Cancer. 2003 Sep;10(3):389-96 [14503915.001]

[Cites] Anal Biochem. 2005 May 1;340(1):165-70 [15802142.001]

[Cites] Anal Chem. 2005 Jul 1;77(13):3979-85 [15987100.001]

[Cites] Bioorg Med Chem Lett. 2004 Feb 23;14(4):847-50 [15012979.001]

[Cites] Biochem J. 2002 Sep 15;366(Pt 3):977-81 [12119045.001]

[Cites] Biochim Biophys Acta. 2004 Mar 11;1697(1-2):39-51 [15023349.001]

[Cites] J Am Soc Mass Spectrom. 2005 Jun;16(6):940-7 [15907708.001]

[Cites] Anal Chem. 2005 Dec 15;77(24):7845-51 [16351129.001]

[Cites] Cancer Metastasis Rev. 2005 Jun;24(2):287-300 [15986138.001]

[Cites] Biochem J. 1993 Sep 1;294 ( Pt 2):335-7 [8373348.001]

[Cites] Melanoma Res. 2004 Apr;14(2):85-9 [15057036.001]

[Cites] Biomacromolecules. 2002 Sep-Oct;3(5):905-9 [12217034.001]

[Cites] Curr Opin Cell Biol. 1990 Apr;2(2):192-7 [2194521.001]

[Cites] J Control Release. 2006 Jan 10;110(2):431-6 [16309776.001]

[Cites] Biochem J. 1993 Apr 15;291 ( Pt 2):329-43 [8484714.001]

[Cites] J Am Soc Mass Spectrom. 2005 Dec;16(12):2027-38 [16253516.001]

(PMID = 17046276.001).

[ISSN] 1044-0305

[Journal-full-title] Journal of the American Society for Mass Spectrometry

[ISO-abbreviation] J. Am. Soc. Mass Spectrom.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Indoles; 0 / Maleimides; 0 / Peptides; 125313-65-7 / Ro 31-7549; EC 2.7.- / Protein Kinases; EC 2.7.11.13 / Protein Kinase C

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

RhoA controls changes in cell morphology and invasion associated with cancer phenotypes.

Cell lines derived from melanoma tumors at varying stages revealed that RhoA is selectively activated in cells of metastatic origin.

MedlinePlus Health Information. consumer health - Melanoma.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. (L)-Methionine .

SciCrunch. HGNC: Data: Gene Annotation .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]

[Cites] Annu Rev Cell Dev Biol. 2005;21:247-69 [16212495.001]

[Cites] Mol Pharmacol. 1997 Nov;52(5):903-11 [9351982.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3726-30 [9520434.001]

[Cites] Mol Carcinog. 1998 Nov;23(3):132-43 [9833774.001]

[Cites] J Cell Sci. 2001 Oct;114(Pt 20):3583-90 [11707510.001]

[Cites] J Invest Dermatol. 2006 Apr;126(4):862-8 [16470169.001]

[Cites] Nat Cell Biol. 1999 Jul;1(3):136-43 [10559899.001]

[Cites] J Neurobiol. 2000 Aug;44(2):126-44 [10934317.001]

[Cites] Nature. 2000 Aug 3;406(6795):532-5 [10952316.001]

[Cites] Methods Enzymol. 2000;325:264-72 [11036609.001]

[Cites] Oncogene. 2001 Apr 19;20(17):2112-21 [11360195.001]

[Cites] Nature. 2001 May 24;411(6836):494-8 [11373684.001]

[Cites] Nat Cell Biol. 2001 Aug;3(8):723-9 [11483957.001]

[Cites] Nat Cell Biol. 2002 Apr;4(4):E97-100 [11944043.001]

[Cites] Crit Rev Oncol Hematol. 2002 Oct;44(1):1-15 [12398996.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):183-8 [12518064.001]

[Cites] Nat Rev Cancer. 2002 Feb;2(2):133-42 [12635176.001]

[Cites] Lab Invest. 2003 Jun;83(6):861-70 [12808121.001]

[Cites] Nat Cell Biol. 2003 Aug;5(8):711-9 [12844144.001]

[Cites] Curr Opin Cell Biol. 2003 Oct;15(5):583-9 [14519393.001]

[Cites] Science. 2003 Oct 10;302(5643):286-90 [14551435.001]

[Cites] J Biochem. 2003 Sep;134(3):309-13 [14561714.001]

[Cites] Biochemistry. 2004 Jan 13;43(1):9-18 [14705926.001]

[Cites] Nat Cell Biol. 2004 Feb;6(2):154-61 [14743221.001]

[Cites] J Biol Chem. 2004 Feb 13;279(7):6196-203 [14645234.001]

[Cites] Clin Cancer Res. 2004 Feb 1;10(3):1192-200 [14871999.001]

[Cites] Trends Plant Sci. 2004 May;9(5):221-8 [15130547.001]

[Cites] BMC Microbiol. 2004 Mar 4;4:9 [15102328.001]

[Cites] Methods Mol Biol. 2004;284:37-49 [15173607.001]

[Cites] J Biol Chem. 2004 Aug 27;279(35):37087-94 [15215245.001]

[Cites] Oncogene. 2004 Oct 18;23(48):7928-46 [15489911.001]

[Cites] J Natl Cancer Inst. 1973 Nov;51(5):1417-23 [4357758.001]

[Cites] In Vitro. 1979 May;15(5):342-50 [478563.001]

[Cites] J Biol Chem. 1983 Jun 10;258(11):6717-20 [6853500.001]

[Cites] J Natl Cancer Inst. 1985 Feb;74(2):283-9 [3856042.001]

[Cites] J Biol Chem. 1988 Jul 15;263(20):9598-606 [2838472.001]

[Cites] Oncogene. 1995 Mar 2;10(5):827-33 [7898924.001]

[Cites] J Virol. 1995 Jun;69(6):3920-3 [7745747.001]

[Cites] Cancer Res. 1996 Mar 1;56(5):1083-90 [8640765.001]

[Cites] Melanoma Res. 1997 Aug;7 Suppl 2:S35-42 [9578415.001]

[Cites] Mol Cancer Ther. 2006 May;5(5):1136-44 [16731745.001]

[Cites] Mol Cell Proteomics. 2006 Aug;5(8):1359-67 [16644720.001]

[Cites] J Biol Chem. 2007 Jul 20;282(29):21477-86 [17548352.001]

[Cites] Protein Sci. 2008 Jan;17(1):126-35 [18156470.001]

[Cites] Cell. 2008 Oct 31;135(3):510-23 [18984162.001]

[Cites] J Cell Biochem. 2009 Feb 1;106(2):210-9 [19097084.001]

[Cites] Science. 1996 Jul 12;273(5272):245-8 [8662509.001]

(PMID = 19620624.001).

[ISSN] 1535-9484

[Journal-full-title] Molecular & cellular proteomics : MCP

[ISO-abbreviation] Mol. Cell Proteomics

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P50 CA058187; United States / NCI NIH HHS / CA / F32 CA105796; United States / NCI NIH HHS / CA / R01-CA126240; United States / NIGMS NIH HHS / GM / T32 GM008759; United States / NCI NIH HHS / CA / R01-CA118972; United States / NIGMS NIH HHS / GM / T32-GM008759; United States / NCI NIH HHS / CA / R01 CA118972; United States / NCI NIH HHS / CA / P50-CA058187; United States / NCI NIH HHS / CA / F32 CA112847; United States / NCI NIH HHS / CA / F32-CA112847; United States / NIAID NIH HHS / AI / R01-AI060841; United States / NCI NIH HHS / CA / F32-CA105796; United States / NCI NIH HHS / CA / R01 CA126240; United States / NIAID NIH HHS / AI / R01 AI060841

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 7LP2MPO46S / S-Adenosylmethionine; AE28F7PNPL / Methionine; EC 3.6.5.2 / rhoA GTP-Binding Protein; EC 5.3.1.- / Aldose-Ketose Isomerases; EC 5.3.1.23 / MRDI protein, human

[Other-IDs] NLM/ PMC2758758

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cell-cell electrofusion: optimization of electric field amplitude and hypotonic treatment for mouse melanoma (B16-F1) and Chinese Hamster ovary (CHO) cells.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Anal Biochem. 2002 Mar 15;302(2):213-9 [11878799.001]

[Cites] J Immunol Methods. 1987 Jun 26;100(1-2):5-40 [3298441.001]

[Cites] Biochemistry. 1995 Jul 11;34(27):8520-32 [7612594.001]

[Cites] Bioelectrochemistry. 2004 Jun;63(1-2):327-32 [15110297.001]

[Cites] J Immunol Methods. 2008 Jul 31;336(2):142-51 [18514220.001]

[Cites] Plant Physiol. 1988 Jun;87(2):389-94 [16666152.001]

[Cites] Nat Rev Mol Cell Biol. 2008 Jul;9(7):543-56 [18496517.001]

[Cites] Proc Natl Acad Sci U S A. 1986 Oct;83(19):7132-6 [3463955.001]

[Cites] Radiol Oncol. 2010 Mar;44(1):34-41 [22933889.001]

[Cites] Hybridoma. 1988 Oct;7(5):505-18 [3198135.001]

[Cites] Cancer Immunol Immunother. 1994 Nov;39(5):342-5 [7987867.001]

[Cites] Am J Physiol Cell Physiol. 2007 Jul;293(1):C390-400 [17537804.001]

[Cites] IEEE Trans Biomed Eng. 2009 May;56(5):1491-501 [19203876.001]

[Cites] Biophys J. 1999 Apr;76(4):2090-8 [10096904.001]

[Cites] Biochem Biophys Res Commun. 2006 Aug 4;346(3):829-39 [16780801.001]

[Cites] Cancer Immun. 2002 Nov 07;2:15 [12747760.001]

[Cites] Anal Biochem. 1986 Nov 15;159(1):109-13 [3812988.001]

[Cites] Nature. 1976 Jul 1;262(5563):52-4 [180426.001]

[Cites] J Membr Biol. 2005 Aug;206(3):187-201 [16456714.001]

[Cites] Methods Mol Biol. 1995;48:355-63 [8528407.001]

[Cites] Biochim Biophys Acta. 1982 Nov 30;694(3):227-77 [6758848.001]

[Cites] J Membr Biol. 1993 Feb;132(1):27-40 [8459447.001]

[Cites] Exp Cell Res. 1984 Feb;150(2):477-82 [6692859.001]

[Cites] J Membr Biol. 2009 May;229(1):11-8 [19418087.001]

[Cites] J Cell Sci. 1991 Nov;100 ( Pt 3):431-42 [1808197.001]

[Cites] Bioelectrochemistry. 2008 Nov;74(1):124-9 [18667367.001]

[Cites] Biochem Biophys Res Commun. 2004 Feb 13;314(3):717-23 [14741694.001]

[Cites] Biophys J. 1998 Jun;74(6):3015-22 [9635756.001]

[Cites] Biochim Biophys Acta. 2000 Mar 17;1500(3):265-79 [10699368.001]

[Cites] Biochem Biophys Res Commun. 1986 Oct 15;140(1):258-66 [3778446.001]

[Cites] Biophys J. 1991 May;59(5):1074-84 [1868154.001]

[Cites] Biochim Biophys Acta. 2008 Feb;1778(2):483-90 [17996722.001]

[Cites] FEBS Lett. 1985 Mar 25;182(2):278-80 [3979550.001]

[Cites] Biophys J. 1994 Oct;67(4):1574-81 [7819489.001]

[Cites] Biochim Biophys Acta. 2000 Dec 15;1524(2-3):118-30 [11113558.001]

[Cites] Methods Enzymol. 1993;220:174-96 [8350753.001]

[Cites] Anticancer Res. 2009 Aug;29(8):3125-30 [19661325.001]

[Cites] Biochim Biophys Acta. 1986 Jun 13;858(1):206-16 [3707962.001]

[Cites] J Immunol Methods. 1990 Nov 6;134(1):35-42 [2172386.001]

[Cites] Eur J Biochem. 1989 Jan 15;179(1):109-15 [2645133.001]

[Cites] Science. 1982 Apr 30;216(4545):537-8 [7071601.001]

[Cites] Biochemistry. 1990 May 15;29(19):4561-7 [2372540.001]

[Cites] Biochim Biophys Acta. 1989 Jun 6;981(2):295-302 [2567186.001]

[Cites] Biochim Biophys Acta. 1990 May 16;1034(2):125-31 [2354188.001]

[Cites] Biochim Biophys Acta. 1984 Sep 5;775(3):446-8 [6466684.001]

[Cites] J Membr Biol. 1985;85(3):269-80 [3897548.001]

[Cites] J Cell Biol. 1986 Apr;102(4):1358-62 [3958050.001]

[Cites] AAPS PharmSci. 2002;4(4):E21 [12645993.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2715-8 [10688917.001]

[Cites] Biochim Biophys Acta. 1989 Jul 24;983(1):42-50 [2758049.001]

[Cites] Mol Biotechnol. 2009 Oct;43(2):167-76 [19562526.001]

[Cites] Eur Biophys J. 2006 Feb;35(3):196-204 [16215750.001]

[Cites] Bioelectrochemistry. 2004 Apr;62(1):73-82 [14990328.001]

[Cites] J Immunol. 1979 Jun;122(6):2498-504 [312871.001]

[Cites] Biophys J. 1998 Apr;74(4):1889-98 [9545050.001]

[Cites] Biochim Biophys Acta. 1989 Nov 3;985(3):334-8 [2804114.001]

[Cites] Otolaryngol Head Neck Surg. 2005 May;132(5):755-64 [15886631.001]

[Cites] Clin Immunol. 2002 Jul;104(1):14-20 [12139943.001]

[Cites] Biophys J. 1992 Mar;61(3):810-5 [1504251.001]

[Cites] Cancer Immunol Immunother. 2002 Sep;51(7):367-75 [12192536.001]

[Cites] Mol Biotechnol. 2009 Mar;41(3):286-95 [19016008.001]

[Cites] FEBS Lett. 2007 May 22;581(11):2181-93 [17395182.001]

[Cites] Technol Cancer Res Treat. 2007 Feb;6(1):37-48 [17241099.001]

[Cites] Biochim Biophys Acta. 1993 Nov 7;1152(2):207-18 [8218321.001]

[Cites] J Med Microbiol. 2007 Jun;56(Pt 6):733-7 [17510256.001]

(PMID = 20628737.001).

[ISSN] 1432-1424

[Journal-full-title] The Journal of membrane biology

[ISO-abbreviation] J. Membr. Biol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

Advertisement

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Radiculopathy due to malignant melanoma in the sacrum with unknown primary site.

Melanoma is an interesting tumor, showing the appearance of metastasis without any trace of its primary lesion.

To report a very rare case of malignant melanoma in the sacrum with unknown primary origin.

The pathological diagnosis was malignant melanoma.

No obvious primary malignant melanoma was detected on the skin surface, on the oral or anal mucosa, or in the fundus oculi.

However the patient died nine months after initial diagnosis.

Malignant melanoma in the sacrum with an unknown primary site, showing S1 radiculopathy is reported for the first time.

The melanoma could have been a metastatic tumor of the sacrum, although the primary site was not detected.

The incidence of primary melanoma is increasing faster than any other cancer.

Thus treatment of patients with spinal metastasis of melanoma is an important challenge for orthopedic surgeons.

[MeSH-major] Melanoma / secondary. Neoplasms, Unknown Primary / pathology. Radiculopathy / etiology. Radiculopathy / pathology. Sacrum / pathology. Spinal Neoplasms / secondary

MedlinePlus Health Information. consumer health - Melanoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Melanoma Res. 2000 Feb;10(1):78-80 [10711643.001]

[Cites] Cancer. 1997 May 1;79(9):1816-21 [9129001.001]

[Cites] Cancer. 1970 Oct;26(4):816-20 [5506606.001]

[Cites] Oncology. 1972;26(2):265-70 [5049921.001]

[Cites] Cancer. 1972 Dec;30(6):1469-72 [4641758.001]

[Cites] Br J Surg. 1977 Nov;64(11):805-8 [588977.001]

[Cites] JAMA. 1979 Jan 26;241(4):381-3 [758556.001]

[Cites] Br Med J. 1979 Jun 9;1(6177):1530-3 [466103.001]

[Cites] Ann Surg. 1980 Jan;191(1):98-104 [7352784.001]

[Cites] Clin Orthop Relat Res. 1982 Sep;(169):95-102 [7105592.001]

[Cites] CA Cancer J Clin. 1991 Jul-Aug;41(4):201-26 [2049635.001]

[Cites] Cancer. 1991 Dec 15;68(12):2579-81 [1933805.001]

[Cites] Spine (Phila Pa 1976). 1995 Oct 1;20(19):2141-6 [8588172.001]

[Cites] Arch Phys Med Rehabil. 1996 Mar;77(3):307-9 [8600878.001]

[Cites] Br J Surg. 1967 Jul;54(7):651-8 [6026989.001]

(PMID = 18075762.001).

[ISSN] 1432-0932

[Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society

[ISO-abbreviation] Eur Spine J

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

[Other-IDs] NLM/ PMC2525896

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Brain metastases of malignant melanomas were induced by injecting tumor cells into the carotid artery of mice.

Possible reasons why metastatic cells of malignant melanomas were not identified in FTIR images are discussed.

[MeSH-minor] Animals. Automatic Data Processing. Brain / pathology. Cell Line, Tumor. Cluster Analysis. Female. Humans. Melanoma / pathology. Mice. Mice, Nude. Neoplasm Transplantation. Optical Fibers. Spectroscopy, Fourier Transform Infrared / methods. Transplantation, Heterologous

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Diagnostic Imaging.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17639353.001).

[ISSN] 1618-2642

[Journal-full-title] Analytical and bioanalytical chemistry

[ISO-abbreviation] Anal Bioanal Chem

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Melanoma adrenal metastasis: report of 3 cases and literature review].

OBJECTIVE: To investigate the clinical diagnosis, treatment and prognosis of melanoma adrenal metastasis.

METHODS: A total of 48 cases of malignant melanoma from 1985 to 2007 were reviewed.

And three cases of melanoma adrenal metastasis were analyzed.

Two cases had a history of cutaneous melanoma and another one suffered previously from anal melanoma.

The other two cases underwent complete resection of melanoma metastasis.

When contralateral adrenal metastasis of melanoma was found 6 months later, left adrenalectomy laparoscopically was performed.

CONCLUSION: Melanoma metastasis to adrenal gland is rare and it generally has a poor prognosis.

Patients with adrenal metastases from melanoma, either isolated or with a limited number of additional metastases, may achieve a survival benefit from surgical resection if all visible lesions are removed.

[MeSH-major] Adrenal Gland Neoplasms / secondary. Melanoma / pathology. Skin Neoplasms / pathology

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20646432.001).

[ISSN] 0376-2491

[Journal-full-title] Zhonghua yi xue za zhi

[ISO-abbreviation] Zhonghua Yi Xue Za Zhi

[Language] chi

[Publication-type] Case Reports; English Abstract; Journal Article; Review

[Publication-country] China

[Number-of-references] 8

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.

BACKGROUND: HLA-A2 tetramer flow cytometry, IFNgamma real time RT-PCR and IFNgamma ELISPOT assays are commonly used as surrogate immunological endpoints for cancer immunotherapy.

HLA-A2 (A*0201) tetramer assay specific for gp100209(210M) and MART-126-35(27L), IFNgamma real time RT-PCR and ELISPOT methods were validated using tumor infiltrating lymphocyte cell lines (TIL) isolated from HLA-A2 melanoma patients.

A positive IFNgamma response (by RT-PCR and ELISPOT) to gp100 was demonstrated in PBMC from 3 melanoma patients.

These methods can be applied not only to cancer vaccines but to other therapeutic proteins as part of immunogenicity and safety analyses.

[MeSH-major] Antigens, Neoplasm / immunology. Enzyme-Linked Immunosorbent Assay / methods. Flow Cytometry / methods. HLA-A2 Antigen / immunology. Interferon-gamma / genetics. Melanoma / immunology. Membrane Glycoproteins / immunology. Neoplasm Proteins / immunology. Reverse Transcriptase Polymerase Chain Reaction / methods

[MeSH-minor] Calibration. Cell Line, Tumor. Humans. MART-1 Antigen. Reference Standards. Reproducibility of Results. Sensitivity and Specificity. gp100 Melanoma Antigen

MedlinePlus Health Information. consumer health - Melanoma.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Immunol. 1999 Dec 1;163(11):6292-300 [10570323.001]

[Cites] J Clin Invest. 2005 Jul;115(7):1903-12 [15937544.001]

[Cites] J Pharm Biomed Anal. 2000 Jan;21(6):1249-73 [10708409.001]

[Cites] J Immunol. 2000 Aug 15;165(4):2287-96 [10925318.001]

[Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1336-44 [10944556.001]

[Cites] Cancer Chemother Pharmacol. 2000;46 Suppl:S62-6 [10950150.001]

[Cites] J Immunol. 2000 Dec 1;165(11):6644-52 [11086110.001]

[Cites] Scand J Immunol. 2000 Dec;52(6):544-9 [11119258.001]

[Cites] Int J Cancer. 2002 Mar 20;98(3):376-88 [11920589.001]

[Cites] Clin Cancer Res. 2002 Apr;8(4):1021-32 [11948109.001]

[Cites] J Immunother. 2002 Mar-Apr;25(2):97-138 [12074049.001]

[Cites] Clin Cancer Res. 2003 Feb;9(2):641-9 [12576430.001]

[Cites] Clin Cancer Res. 2003 Apr;9(4):1301-12 [12684398.001]

[Cites] Cancer Immunol Immunother. 2004 Aug;53(8):715-22 [14997347.001]

[Cites] J Immunother. 2004 Jul-Aug;27(4):298-308 [15235391.001]

[Cites] J Immunol Methods. 2004 Aug;291(1-2):175-83 [15345315.001]

[Cites] J Immunol. 1999 Feb 15;162(4):2227-34 [9973498.001]

[Cites] J Exp Med. 1999 Sep 6;190(5):651-67 [10477550.001]

[Cites] J Exp Med. 1999 Sep 6;190(5):705-15 [10477554.001]

[Cites] J Clin Oncol. 2005 Feb 1;23(4):741-50 [15613700.001]

[Cites] Methods Mol Biol. 2005;302:51-86 [15937345.001]

[Cites] Clin Diagn Lab Immunol. 2000 Mar;7(2):145-54 [10702485.001]

(PMID = 18945350.001).

[ISSN] 1479-5876

[Journal-full-title] Journal of translational medicine

[ISO-abbreviation] J Transl Med

[Language] eng

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / HLA-A2 Antigen; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / PMEL protein, human; 0 / gp100 Melanoma Antigen; 82115-62-6 / Interferon-gamma

[Other-IDs] NLM/ PMC2605437

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Melanoma of the anal canal.

[MeSH-major] Anus Neoplasms / pathology. Melanoma / secondary

MedlinePlus Health Information. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Melanoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Chir Ital. 2003 Jul-Aug;55(4):575-80 [12938606.001]

[Cites] Dis Colon Rectum. 1995 Feb;38(2):146-51 [7851168.001]

[Cites] Eur J Surg Oncol. 1996 Dec;22(6):598-601 [9005147.001]

[Cites] Am J Surg. 2005 Apr;189(4):446-9 [15820458.001]

[Cites] Ai Zheng. 2006 May;25(5):619-24 [16687086.001]

[Cites] Dis Colon Rectum. 2010 Apr;53(4):402-8 [20305438.001]

[Cites] Dis Colon Rectum. 2007 Jul;50(7):1004-10 [17468984.001]

[Cites] Trop Gastroenterol. 2007 Apr-Jun;28(2):76-8 [18050846.001]

[Cites] Zentralbl Chir. 2007 Dec;132(6):560-3 [18098086.001]

[Cites] Acta Chir Belg. 2008 Nov-Dec;108(6):756-8 [19241934.001]

[Cites] Eur J Surg Oncol. 2009 Jul;35(7):757-62 [18602790.001]

[Cites] Am Surg. 2006 Oct;72(10):917-20 [17058735.001]

(PMID = 21120314.001).

[ISSN] 1980-5322

[Journal-full-title] Clinics (São Paulo, Brazil)

[ISO-abbreviation] Clinics (Sao Paulo)

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] Brazil

[Other-IDs] NLM/ PMC2972593

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells.

To identify C-MYC targets rate-limiting for proliferation of malignant melanoma, we stably inhibited C-MYC in several human metastatic melanoma lines via lentivirus-based shRNAs approximately to the levels detected in normal melanocytes.

C-MYC depletion also resulted in reduction in the amounts of deoxyribonucleoside triphosphates (dNTPs) and inhibition of proliferation. shRNA-mediated suppression of TS, IMPDH2 or PRPS2 resulted in the decrease of dNTP pools and retardation of the cell cycle progression of melanoma cells in a manner similar to that of C-MYC-depletion in those cells.

Reciprocally, concurrent overexpression of cDNAs for TS, IMPDH2 and PRPS2 delayed proliferative arrest caused by inhibition of C-MYC in melanoma cells.

Moreover, all three proteins express at higher levels in cells from several metastatic melanoma lines compared to normal melanocytes.

MedlinePlus Health Information. consumer health - Melanoma.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Mol Cell. 2002 May;9(5):1031-44 [12049739.001]

[Cites] Mutat Res. 2002 Feb 20;499(2):197-211 [11827713.001]

[Cites] Curr Cancer Drug Targets. 2003 Jun;3(3):163-75 [12769686.001]

[Cites] Genome Biol. 2003;4(10):R69 [14519204.001]

[Cites] J Biol Chem. 2003 Nov 7;278(45):43893-6 [13679382.001]

[Cites] Nat Rev Cancer. 2004 Jul;4(7):562-8 [15229481.001]

[Cites] Int J Cancer. 2004 Dec 10;112(5):733-7 [15386371.001]

[Cites] Cell Cycle. 2004 Aug;3(8):1005-7 [15280655.001]

[Cites] Anal Biochem. 1992 Oct;206(1):178-82 [1456431.001]

[Cites] Mol Cell Biol. 1993 Sep;13(9):5216-24 [8395000.001]

[Cites] J Biol Chem. 1993 Dec 25;268(36):27277-85 [8262968.001]

[Cites] Mol Cell Biol. 1995 May;15(5):2527-35 [7739536.001]

[Cites] Cell Growth Differ. 1997 Oct;8(10):1039-48 [9342182.001]

[Cites] Pharmacol Ther. 1997 Oct-Dec;76(1-3):29-43 [9535167.001]

[Cites] Nat Genet. 1999 Feb;21(2):220-4 [9988278.001]

[Cites] Oncogene. 1999 May 13;18(19):3004-16 [10378696.001]

[Cites] Curr Med Chem. 1999 Jul;6(7):545-60 [10390600.001]

[Cites] EMBO J. 1999 Oct 1;18(19):5321-33 [10508165.001]

[Cites] Anticancer Res. 2004 Nov-Dec;24(6):3875-80 [15736425.001]

[Cites] Cancer Res. 2005 Mar 15;65(6):2097-107 [15781619.001]

[Cites] Cancer Res. 2005 Jul 15;65(14):6294-304 [16024631.001]

[Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):635-45 [16064138.001]

[Cites] Curr Top Microbiol Immunol. 2006;302:33-50 [16620024.001]

[Cites] Curr Top Microbiol Immunol. 2006;302:51-62 [16620025.001]

[Cites] Curr Top Microbiol Immunol. 2006;302:123-43 [16620027.001]

[Cites] Curr Top Microbiol Immunol. 2006;302:145-67 [16620028.001]

[Cites] Cell Death Differ. 2006 Jun;13(6):951-61 [16575405.001]

[Cites] Cancer Res. 2006 Jul 1;66(13):6598-605 [16818632.001]

[Cites] Semin Cancer Biol. 2006 Aug;16(4):253-64 [16904903.001]

[Cites] Semin Cancer Biol. 2006 Aug;16(4):313-7 [16935001.001]

[Cites] Oncogene. 2006 Oct 30;25(51):6817-30 [17072330.001]

[Cites] EMBO Rep. 2007 Jan;8(1):70-6 [17159920.001]

[Cites] Oncogene. 2008 Mar 20;27(13):1905-15 [17906696.001]

[Cites] Mol Cell Biol. 2002 Aug;22(16):5793-800 [12138190.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2229-34 [10688915.001]

[Cites] Genes Dev. 2001 Aug 15;15(16):2023-30 [11511533.001]

[Cites] Mol Cell. 2001 Jul;8(1):105-13 [11511364.001]

[Cites] Prog Nucleic Acid Res Mol Biol. 2001;69:115-48 [11550793.001]

[CommentIn] Cell Cycle. 2008 Aug;7(15):2275-6 [18682683.001]

(PMID = 18677108.001).

[ISSN] 1551-4005

[Journal-full-title] Cell cycle (Georgetown, Tex.)

[ISO-abbreviation] Cell Cycle

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA083081; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NCI NIH HHS / CA / R01 CA076581; United States / NCI NIH HHS / CA / R01-CA120244-A1; United States / NCI NIH HHS / CA / R01 CA120244

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Nucleotides; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Small Interfering; EC 1.1.1.205 / IMP Dehydrogenase; EC 1.1.1.205 / IMPDH2 protein, human; EC 2.1.1.45 / Thymidylate Synthase; EC 2.7.6.1 / Ribose-Phosphate Pyrophosphokinase

[Other-IDs] NLM/ NIHMS486377; NLM/ PMC3744895

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Late recurrence of malignant melanoma in the duodenum.

Melanoma is a malignancy originating from melanocytes.

The primary melanoma usually occurs on the skin, retina, anal canal or occasionally at other organs such as the esophagus, penis or vagina.

Although melanoma represents about one-third of all metastatic lesions in the gastrointestinal tract, metastasis of melanoma to the GI tract, detected radiologically or endoscopically, is relatively rare.

In most cases of malignant melanoma, recurrence and death occur within 10 years after treatment of the primary lesion.

We herein report a case showing a recurrence 17 years after extirpation of primary malignant melanoma in the foot.

A 65-year-old man, with a history of extirpation of a malignant melanoma in the sole of his foot 17 years before, presented with anorexia and severe anemia, and multiple duodenal tumors were pointed out with upper gastrointestinal endoscopy.

Histologic examination of the endoscopic biopsy specimen revealed proliferation of large polygonal cells with distinct nucleoli, and malignant melanoma was diagnosed immunohistochemically.

[MeSH-major] Duodenal Neoplasms / pathology. Melanoma / pathology. Neoplasm Recurrence, Local / pathology

MedlinePlus Health Information. consumer health - Intestinal Cancer.

MedlinePlus Health Information. consumer health - Melanoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19102354.001).

[ISSN] 0172-6390

[Journal-full-title] Hepato-gastroenterology

[ISO-abbreviation] Hepatogastroenterology

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Greece

[Chemical-registry-number] 0 / CC chemokine receptor 9; 0 / Receptors, CCR

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line.

Apomine, a novel bisphosphonate ester, has demonstrated anticancer activity in a variety of cancer cell lines; however, its mechanism of cytotoxicity is not well understood.

Previous work has demonstrated that Apomine induces cell death by activation of caspase-3 in several cancer cell types.

However, we have demonstrated that Apomine induces cell death in the A375 human melanoma cell line through a novel membrane-mediated mechanism that is independent of caspase-3 activation.

Interestingly, Apomine-mediated cell death in the A375 and UACC 3093 human melanoma cell lines is also independent of N-Ras farnesylation, which was a previously described mechanism of action for Apomine in other cancer cell types.

[MeSH-major] Antineoplastic Agents / toxicity. Apoptosis / drug effects. Cell Membrane / drug effects. Diphosphonates / toxicity. Melanoma / drug therapy

MedlinePlus Health Information. consumer health - Melanoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Immunol Methods. 1988 Nov 25;115(1):61-9 [3192948.001]

[Cites] Cancer Treat Rev. 2004 Nov;30(7):609-41 [15531395.001]

[Cites] Biochim Biophys Acta. 2005 Jun 15;1735(1):59-67 [15951237.001]

[Cites] Clin Cancer Res. 2002 Nov;8(11):3468-74 [12429636.001]

[Cites] Cancer Lett. 2000 Apr 28;152(1):107-13 [10754212.001]

[Cites] Leukemia. 2003 Feb;17(2):451-7 [12592346.001]

[Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]

[Cites] Invest New Drugs. 2006 Jan;24(1):89-94 [16379038.001]

[Cites] Biochem Biophys Res Commun. 2005 Apr 8;329(2):772-9 [15737653.001]

[Cites] Int J Hyperthermia. 1989 May-Jun;5(3):329-40 [2498438.001]

[Cites] Anticancer Drugs. 1997 Mar;8(3):245-56 [9095329.001]

[Cites] Cancer Res. 1975 Nov;35(11 Pt 1):3009-13 [1182696.001]

[Cites] Nucleic Acids Res. 1983 Mar 11;11(5):1475-89 [6828386.001]

[Cites] Clin Cancer Res. 2001 May;7(5):1246-50 [11350890.001]

[Cites] Cancer Genet Cytogenet. 1995 Sep;83(2):93-104 [7553595.001]

[Cites] Biochem Biophys Res Commun. 2000 Apr 2;270(1):240-6 [10733934.001]

[Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]

[Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1062-74 [11459867.001]

[Cites] Cancer Genet Cytogenet. 1998 Dec;107(2):89-92 [9844599.001]

[Cites] J Am Coll Surg. 2005 Mar;200(3):362-70 [15737846.001]

[Cites] Int J Cancer. 2005 May 20;115(1):65-73 [15688405.001]

[Cites] J Biol Chem. 2004 Feb 20;279(8):6465-73 [14627708.001]

[Cites] Cancer Res. 2001 Jan 1;61(1):131-7 [11196150.001]

[Cites] J Immunol Methods. 1983 Nov 25;64(3):313-20 [6199426.001]

[Cites] J Cell Physiol. 1984 Jan;118(1):27-33 [6418750.001]

[Cites] Cell Tissue Kinet. 1990 Nov;23(6):603-17 [2276175.001]

[Cites] J Pharm Biomed Anal. 2006 Mar 3;40(4):975-80 [16181759.001]

[Cites] J Supramol Struct. 1976;4(1):127-32 [1256059.001]

[Cites] Toxicol Appl Pharmacol. 2000 Mar 1;163(2):195-202 [10698678.001]

[Cites] Carcinogenesis. 1999 Sep;20(9):1747-53 [10469620.001]

[Cites] Biochemistry. 2002 Nov 19;41(46):13698-704 [12427032.001]

[Cites] Nutr Cancer. 1998;31(2):111-8 [9770722.001]

(PMID = 17024575.001).

[ISSN] 0167-6997

[Journal-full-title] Investigational new drugs

[ISO-abbreviation] Invest New Drugs

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA23074; United States / NCI NIH HHS / CA / CA27502

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Neoplasm; 0 / Diphosphonates; 0 / apomine; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspases; EC 3.6.5.2 / ras Proteins; VC2W18DGKR / Thymidine

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Methylthioadenosine (MTA) inhibits melanoma cell proliferation and in vivo tumor growth.

BACKGROUND: Melanoma is the most deadly form of skin cancer without effective treatment.

In this study we have assessed the therapeutic potential of MTA in melanoma treatment.

METHODS: To investigate the therapeutic potential of MTA we performed in vitro proliferation and viability assays using six different mouse and human melanoma cell lines wild type for RAS and BRAF or harboring different mutations in RAS pathway.

We also have tested its therapeutic capabilities in vivo in a xenograft mouse melanoma model and using variety of molecular techniques and tissue culture we investigated its anti-proliferative and pro-apoptotic properties.

RESULTS: In vitro experiments showed that MTA treatment inhibited melanoma cell proliferation and viability in a dose dependent manner, where BRAF mutant melanoma cell lines appear to be more sensitive.

CONCLUSIONS: MTA inhibits melanoma cell proliferation and in vivo tumor growth particularly in BRAF mutant melanoma cells.

These data reveal a naturally occurring drug potentially useful for melanoma treatment.

[MeSH-major] Adenosine / pharmacology. Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Melanoma / drug therapy. Skin Neoplasms / drug therapy. Thionucleosides / pharmacology

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

Hazardous Substances Data Bank. Adenosine .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Res. 1984 Jun;44(6):2297-301 [6426777.001]

[Cites] J Biol Chem. 1984 May 10;259(9):5465-71 [6425290.001]

[Cites] Exp Hematol. 1984 Dec;12(11):867-71 [6510486.001]

[Cites] Anal Biochem. 1986 Nov 15;159(1):109-13 [3812988.001]

[Cites] Cancer Res. 1987 Apr 1;47(7):1771-4 [3102048.001]

[Cites] Cancer Res. 1987 Jul 15;47(14):3830-4 [3474063.001]

[Cites] J Cell Physiol. 1987 Nov;133(2):372-6 [3119605.001]

[Cites] Biochim Biophys Acta. 1991 Mar 26;1088(3):365-72 [2015299.001]

[Cites] Mol Cell Biol. 1992 Jan;12(1):103-11 [1729592.001]

[Cites] J Biol Chem. 1993 Feb 25;268(6):4244-9 [8440708.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6489-93 [7604019.001]

[Cites] Exp Cell Res. 1998 May 1;240(2):282-92 [9597001.001]

[Cites] Arch Biochem Biophys. 1964 Jul 20;106:95-100 [14217209.001]

[Cites] Genes Dev. 2006 Aug 15;20(16):2149-82 [16912270.001]

[Cites] Ann Neurol. 2006 Sep;60(3):323-34 [16786535.001]

[Cites] Gastroenterology. 2007 Jul;133(1):207-18 [17631143.001]

[Cites] J Biol Chem. 2007 Jul 20;282(29):21477-86 [17548352.001]

[Cites] J Cell Biochem. 2009 Feb 1;106(2):210-9 [19097084.001]

[Cites] PLoS One. 2009;4(3):e4771 [19274086.001]

[Cites] PLoS One. 2009;4(5):e5735 [19478948.001]

[Cites] Mol Pharmacol. 2009 Jul;76(1):192-200 [19372210.001]

[Cites] Nat Genet. 2009 Aug;41(8):920-5 [19578364.001]

[Cites] Int J Cancer. 2010 Apr 1;126(7):1549-61 [19810100.001]

[Cites] Cell. 2001 Mar 9;104(5):731-41 [11257227.001]

[Cites] J Hepatol. 2001 Mar;34(3):386-94 [11322199.001]

[Cites] FASEB J. 2002 Jan;16(1):15-26 [11772932.001]

[Cites] Hepatology. 2002 Feb;35(2):274-80 [11826399.001]

[Cites] Oncogene. 2002 Feb 7;21(7):1000-8 [11850817.001]

[Cites] Alcohol. 2002 Jul;27(3):193-8 [12163149.001]

[Cites] Mol Endocrinol. 2002 Sep;16(9):2008-18 [12198239.001]

[Cites] Hepatology. 2004 Apr;39(4):1088-98 [15057913.001]

[Cites] Int J Biochem Cell Biol. 2004 Nov;36(11):2125-30 [15313459.001]

[Cites] Cancer Res. 1983 Oct;43(10):4699-702 [6411330.001]

[Cites] Biochem Biophys Res Commun. 1984 Oct 15;124(1):172-7 [6497877.001]

(PMID = 20529342.001).

[ISSN] 1471-2407

[Journal-full-title] BMC cancer

[ISO-abbreviation] BMC Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ribosomal Protein S6; 0 / Thionucleosides; 136601-57-5 / Cyclin D1; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Braf protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; K72T3FS567 / Adenosine

[Other-IDs] NLM/ PMC2891639

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: As a result of advances in skin imaging technology and the development of suitable image processing techniques, during the last decade, there has been a significant increase of interest in the computer-aided diagnosis of melanoma.

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Skin Res Technol. 2005 Feb;11(1):17-26 [15691255.001]

[Cites] IEEE Trans Pattern Anal Mach Intell. 2004 Nov;26(11):1452-8 [15521493.001]

[Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]

[Cites] Skin Res Technol. 2007 Nov;13(4):454-62 [17908199.001]

[Cites] Arch Dermatol. 1995 Mar;131(3):286-91 [7887657.001]

[Cites] J Am Acad Dermatol. 1993 Oct;29(4):581-8 [8408794.001]

[Cites] IEEE Trans Med Imaging. 1999 Feb;18(2):164-71 [10232673.001]

[Cites] Comput Med Imaging Graph. 1998 Sep-Oct;22(5):375-89 [9890182.001]

[Cites] Melanoma Res. 2006 Apr;16(2):183-90 [16567974.001]

(PMID = 19159382.001).

[ISSN] 1600-0846

[Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)

[ISO-abbreviation] Skin Res Technol

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R44 CA060294-02A2; United States / NCI NIH HHS / CA / R44 CA101639; United States / NCI NIH HHS / CA / 2R44 CA-101639-02A2

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] England

[Other-IDs] NLM/ NIHMS317765; NLM/ PMC3160669

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In vertebrates, it regulates the development of several cell types including melanocytes and has also been shown to play an important role in melanoma.

MedlinePlus Health Information. consumer health - Eye Care.

COS Scholar Universe. author profiles.

PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .

Hazardous Substances Data Bank. L-SERINE .

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]

[Cites] Hum Mol Genet. 2000 Jan 1;9(1):125-32 [10587587.001]

[Cites] Genes Dev. 2000 Feb 1;14(3):301-12 [10673502.001]

[Cites] Exp Cell Res. 2000 Mar 15;255(2):135-43 [10694430.001]

[Cites] Genetics. 2000 May;155(1):291-300 [10790403.001]

[Cites] Biochem J. 2001 Oct 1;359(Pt 1):1-16 [11563964.001]

[Cites] J Biol Chem. 2002 Mar 29;277(13):11077-83 [11792706.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4477-82 [11930005.001]

[Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]

[Cites] Nucleic Acids Res. 2003 Aug 1;31(15):e80 [12888532.001]

[Cites] Development. 2004 Jan;131(1):131-42 [14660434.001]

[Cites] J Virol. 1982 Jul;43(1):26-36 [6287001.001]

[Cites] Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2341-5 [1826051.001]

[Cites] Cell. 1993 Jul 30;74(2):395-404 [8343963.001]

[Cites] Genes Dev. 1994 Nov 15;8(22):2770-80 [7958932.001]

[Cites] Nat Genet. 1994 Nov;8(3):256-63 [7874168.001]

[Cites] Nature. 1998 Jan 15;391(6664):298-301 [9440696.001]

[Cites] J Biol Chem. 1998 Jul 17;273(29):17983-6 [9660747.001]

[Cites] Annu Rev Genet. 2004;38:365-411 [15568981.001]

[Cites] Science. 2005 Feb 4;307(5710):720-4 [15618488.001]

[Cites] Nucleic Acids Res. 2005;33(4):e36 [15731329.001]

[Cites] Anal Biochem. 2006 Apr 15;351(2):308-10 [16524557.001]

[Cites] Trends Mol Med. 2006 Sep;12(9):406-14 [16899407.001]

[Cites] Pigment Cell Res. 2007 Feb;20(1):36-40 [17250546.001]

[Cites] Pigment Cell Res. 2007 Jun;20(3):185-200 [17516926.001]

[Cites] Genetics. 2008 Jan;178(1):259-72 [18202372.001]

[Cites] Cell Res. 2008 Dec;18(12):1163-76 [19002157.001]

[Cites] Methods Mol Biol. 2010;647:237-50 [20694671.001]

(PMID = 19635938.001).

[ISSN] 1943-2631

[Journal-full-title] Genetics

[ISO-abbreviation] Genetics

[Language] ENG

[Grant] United States / Intramural NIH HHS / /

[Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Microphthalmia-Associated Transcription Factor; 452VLY9402 / Serine

[Other-IDs] NLM/ PMC2766318

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines.

In vitro cytotoxicity experiments verified that the Co(2+)-substituted human Arg I displays an approximately 12- to 15-fold lower IC(50) value for the killing of human hepatocellular carcinoma and melanoma cell lines and thus constitutes a promising new candidate for the treatment of l-Arg auxotrophic tumors.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .

Hazardous Substances Data Bank. COBALT, ELEMENTAL .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Annu Rev Biochem. 1999;68:33-57 [10872443.001]

[Cites] Science. 2006 Jan 27;311(5760):535-8 [16439663.001]

[Cites] Anal Biochem. 2000 Nov 15;286(2):257-64 [11067748.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3226-31 [11248060.001]

[Cites] Arch Biochem Biophys. 2001 May 1;389(1):135-43 [11370664.001]

[Cites] J Control Release. 2002 Apr 23;80(1-3):259-71 [11943403.001]

[Cites] J Am Chem Soc. 2002 May 15;124(19):5256-7 [11996552.001]

[Cites] Biochemistry. 2003 Jul 1;42(25):7748-58 [12820884.001]

[Cites] Eur J Biochem. 2004 May;271(10):1952-62 [15128304.001]

[Cites] J Clin Oncol. 2004 May 15;22(10):1815-22 [15143074.001]

[Cites] Curr Opin Biotechnol. 2004 Aug;15(4):291-7 [15296927.001]

[Cites] Biochemistry. 1970 Oct 27;9(22):4352-9 [5472710.001]

[Cites] Anal Biochem. 1989 Nov 1;182(2):319-26 [2610349.001]

[Cites] Arch Biochem Biophys. 1991 Apr;286(1):217-21 [1910285.001]

[Cites] Arch Biochem Biophys. 1994 Jul;312(1):31-7 [8031143.001]

[Cites] Biochemistry. 1997 Aug 12;36(32):9847-58 [9245417.001]

[Cites] Biochemistry. 1997 Aug 26;36(34):10558-65 [9265637.001]

[Cites] Biochemistry. 1998 Jun 9;37(23):8539-50 [9622506.001]

[Cites] Structure. 1999 Apr 15;7(4):435-48 [10196128.001]

[Cites] J Clin Pathol. 1961 Jul;14:418-24 [13688207.001]

[Cites] Biomol Eng. 2005 Jun;22(1-3):73-9 [15857786.001]

[Cites] Biochemistry. 2006 Jan 31;45(4):1313-20 [16430228.001]

[Cites] Biochemistry. 2006 Sep 5;45(35):10654-66 [16939217.001]

[Cites] Proteins. 2006 Nov 15;65(3):637-42 [16981206.001]

[Cites] Cancer Res. 2007 Jan 1;67(1):309-17 [17210712.001]

[Cites] BioDrugs. 2008;22(1):53-8 [18215091.001]

[Cites] Int J Cancer. 2009 Apr 1;124(7):1700-6 [19089915.001]

[Cites] Proc Natl Acad Sci U S A. 2009 Jun 16;106 Suppl 1:9995-10000 [19528653.001]

[ErratumIn] ACS Chem Biol. 2010 Aug 20;5(8):797

(PMID = 20050660.001).

[ISSN] 1554-8937

[Journal-full-title] ACS chemical biology

[ISO-abbreviation] ACS Chem. Biol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA 139059; United States / NCI NIH HHS / CA / R01 CA139059; United States / NCI NIH HHS / CA / CA139059-01; United States / NIBIB NIH HHS / EB / P30 EB009998; United States / NCI NIH HHS / CA / R01 CA139059-01

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 3G0H8C9362 / Cobalt; 42Z2K6ZL8P / Manganese; EC 3.5.3.1 / Arginase

[Other-IDs] NLM/ NIHMS170379; NLM/ PMC2842482

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Cutaneous malignant melanoma is considered one of the most deadly human cancers, based on both its penchant for metastatic spread and its typical resistance to currently available therapy.

NRAS and BRAF mutations are rarely found in the same melanoma, suggesting that they may possess important overlapping oncogenic activities.

More surprisingly, we discovered that constitutive RalGEF activation had a major impact on several malignant phenotypes, particularly anchorage-independent growth, indicating that this often overlooked pathway should be more carefully evaluated as a possible therapeutic target.

MedlinePlus Health Information. consumer health - Melanoma.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]

[Cites] Nat Genet. 2009 May;41(5):544-52 [19282848.001]

[Cites] Cancer Cell. 2002 Jul;2(1):5-7 [12150818.001]

[Cites] Genes Dev. 2002 Aug 15;16(16):2045-57 [12183360.001]

[Cites] Cancer Res. 2002 Nov 15;62(22):6724-30 [12438273.001]

[Cites] Cancer Res. 2002 Dec 1;62(23):6997-7000 [12460918.001]

[Cites] Nat Genet. 2003 Jan;33(1):19-20 [12447372.001]

[Cites] Nat Rev Cancer. 2003 Jan;3(1):11-22 [12509763.001]

[Cites] Oncogene. 2003 May 19;22(20):3113-22 [12789288.001]

[Cites] Trends Cell Biol. 2003 Aug;13(8):419-25 [12888294.001]

[Cites] EMBO Rep. 2003 Aug;4(8):800-6 [12856001.001]

[Cites] Cancer Res. 2004 Apr 1;64(7):2338-42 [15059882.001]

[Cites] Cancer Cell. 2004 Aug;6(2):171-83 [15324700.001]

[Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]

[Cites] Mol Cell Biol. 1990 Jun;10(6):2503-12 [2188091.001]

[Cites] EMBO J. 1996 Feb 15;15(4):810-6 [8631302.001]

[Cites] Oncogene. 1998 Jul 2;16(26):3397-402 [9692547.001]

[Cites] Anal Biochem. 1999 Jun 1;270(2):207-19 [10334838.001]

[Cites] Cancer Cell. 2005 Jun;7(6):533-45 [15950903.001]

[Cites] Nat Genet. 2005 Jul;37(7):745-9 [15951821.001]

[Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]

[Cites] Cancer Res. 2005 Aug 15;65(16):7111-20 [16103060.001]

[Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]

[Cites] Mol Cell Biol. 2006 Jan;26(2):727-34 [16382162.001]

[Cites] J Invest Dermatol. 2006 Jan;126(1):154-60 [16417231.001]

[Cites] Genes Dev. 2006 Aug 15;20(16):2149-82 [16912270.001]

[Cites] Cancer Res. 2006 Oct 1;66(19):9483-91 [17018604.001]

[Cites] Cell. 2006 Oct 6;127(1):157-70 [17018283.001]

[Cites] Curr Biol. 2006 Dec 19;16(24):2385-94 [17174914.001]

[Cites] Nature. 2007 Feb 22;445(7130):851-7 [17314971.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):10968-73 [17576930.001]

[Cites] Clin Cancer Res. 2007 Jul 1;13(13):3803-13 [17606711.001]

[Cites] Mol Cell Biol. 2007 Nov;27(21):7538-50 [17709381.001]

[Cites] Mol Cell Biol. 2007 Nov;27(22):8003-14 [17875936.001]

[Cites] Melanoma Res. 2007 Dec;17(6):410-2 [17992125.001]

[Cites] APMIS. 2007 Oct;115(10):1161-76 [18042149.001]

[Cites] Nat Rev Cancer. 2008 Feb;8(2):133-40 [18219307.001]

[Cites] Pigment Cell Melanoma Res. 2008 Feb;21(1):27-38 [18353141.001]

[Cites] Blood. 2008 Apr 1;111(7):3364-72 [18227351.001]

[Cites] J Natl Cancer Inst. 2008 Jun 4;100(11):784-95 [18505964.001]

[Cites] Int J Biochem Cell Biol. 2009 Apr;41(4):757-61 [18950730.001]

[ErratumIn] Oncogene. 2011 Apr 14;30(15):1850

(PMID = 20118982.001).

[ISSN] 1476-5594

[Journal-full-title] Oncogene

[ISO-abbreviation] Oncogene

[Language] ENG

[Grant] United States / Intramural NIH HHS / / ZIA BC008756-22; United States / Intramural NIH HHS / / ZIA BC008756-23; United States / Intramural NIH HHS / / Z99 CA999999; United Kingdom / Wellcome Trust / / 078327; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Cdkn2a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / ral Guanine Nucleotide Exchange Factor; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Braf protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 3.1.3.67 / PTEN Phosphohydrolase

[Other-IDs] NLM/ NIHMS357536; NLM/ PMC3287039

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Melanoma of the anus disguised as hemorrhoids: surgical management illustrated by a case report.

[MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / surgery. Hemorrhoids / diagnosis. Melanoma / diagnosis. Melanoma / surgery

[MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

MedlinePlus Health Information. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Hemorrhoids.

MedlinePlus Health Information. consumer health - Melanoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2002 Dec 1;20(23):4555-8 [12454112.001]

[Cites] Lancet Oncol. 2005 Jun;6(6):438-9 [15925823.001]

[Cites] Br J Cancer. 2003 Dec 1;89(11):2019-22 [14647131.001]

[Cites] Int J Colorectal Dis. 2004 Mar;19(2):121-3 [12942268.001]

[Cites] Cancer. 2004 Apr 1;100(7):1478-83 [15042682.001]

[Cites] Br J Surg. 2004 Sep;91(9):1183-7 [15449271.001]

[Cites] Cancer. 1981 Apr 1;47(7):1891-900 [6164474.001]

[Cites] Surgery. 1990 Jan;107(1):1-9 [2296748.001]

[Cites] Dis Colon Rectum. 1990 Oct;33(10):874-7 [1698595.001]

[Cites] World J Surg. 1992 May-Jun;16(3):478-85 [1589984.001]

[Cites] Am Surg. 1993 Jul;59(7):400-4 [8323072.001]

[Cites] Br J Surg. 1993 Sep;80(9):1194-5 [8402131.001]

[Cites] Dis Colon Rectum. 1994 Sep;37(9):866-74 [8076485.001]

[Cites] Dis Colon Rectum. 1995 Feb;38(2):146-51 [7851168.001]

[Cites] Dis Colon Rectum. 1997 Jun;40(6):661-8 [9194459.001]

[Cites] Am J Surg. 2005 Apr;189(4):446-9 [15820458.001]

[Cites] J Am Coll Surg. 2003 Feb;196(2):206-11 [12595048.001]

(PMID = 17415639.001).

[ISSN] 0163-2116

[Journal-full-title] Digestive diseases and sciences

[ISO-abbreviation] Dig. Dis. Sci.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC1914244

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies.

The immune system recognizes diverse melanoma antigens.

Here, we have investigated 33 biopsies (eight primary and 25 metastases) from 24 melanoma patients (15-72 years old) and describe the correlation between the expression of galectin-3 or galectin-1 and the level of apoptosis of tumor-associated lymphocytes using immunohistochemistry and an in situ nick translation assay.

Considering the complex process of cancer immunoediting, various interacting factors must be considered.

[MeSH-major] Biomarkers / analysis. Biopsy. Galectin 1 / metabolism. Galectin 3 / metabolism. Lymphocytes, Tumor-Infiltrating / metabolism. Melanoma / metabolism

MedlinePlus Health Information. consumer health - Biopsy.

MedlinePlus Health Information. consumer health - Melanoma.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Rheum Dis. 2004 Jun;63(6):636-43 [15140769.001]

[Cites] J Clin Invest. 1993 Mar;91(3):1183-90 [8450047.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14639-45 [15381769.001]

[Cites] Am J Pathol. 2000 Mar;156(3):899-909 [10702407.001]

[Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]

[Cites] J Immunol. 2000 Sep 1;165(5):2331-4 [10946254.001]

[Cites] Clin Cancer Res. 2000 Sep;6(9):3560-4 [10999744.001]

[Cites] Nature. 2001 Apr 26;410(6832):1107-11 [11323675.001]

[Cites] J Immunol. 2001 Nov 15;167(10):5697-707 [11698442.001]

[Cites] J Biol Chem. 2002 Mar 1;277(9):6852-7 [11724777.001]

[Cites] J Exp Med. 2002 May 20;195(10):1303-16 [12021310.001]

[Cites] Trends Immunol. 2002 Jun;23(6):313-20 [12072371.001]

[Cites] Glycobiology. 2002 Oct;12(10):127R-36R [12244068.001]

[Cites] J Immunother. 2003 Jul-Aug;26(4):332-42 [12843795.001]

[Cites] Cancer Res. 2003 Dec 1;63(23):8221-5 [14678978.001]

[Cites] Cancer Res. 2003 Dec 1;63(23):8302-11 [14678989.001]

[Cites] J Immunol. 2004 Feb 1;172(3):1602-11 [14734741.001]

[Cites] J Biol Chem. 2004 Feb 6;279(6):4705-12 [14617626.001]

[Cites] Cancer Cell. 2004 Mar;5(3):241-51 [15050916.001]

[Cites] Exp Cell Res. 2004 May 1;295(2):315-29 [15093732.001]

[Cites] Mol Cell Biol. 2004 May;24(10):4395-406 [15121858.001]

[Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]

[Cites] J Immunol. 1984 Oct;133(4):1710-5 [6206131.001]

[Cites] Nature. 1995 Dec 14;378(6558):736-9 [7501023.001]

[Cites] Circulation. 1996 Sep 15;94(6):1255-62 [8822977.001]

[Cites] Science. 1996 Nov 22;274(5291):1363-6 [8910274.001]

[Cites] Cancer Res. 1997 Dec 1;57(23):5272-6 [9393748.001]

[Cites] Biochim Biophys Acta. 1998 Jan 8;1379(1):97-106 [9468337.001]

[Cites] J Immunol. 1999 Jul 1;163(1):443-7 [10384147.001]

[Cites] J Exp Med. 1999 Aug 2;190(3):385-98 [10430627.001]

[Cites] Cell Death Differ. 2004 Dec;11(12):1277-86 [15297883.001]

[Cites] Am J Pathol. 2004 Dec;165(6):1853-63 [15579430.001]

[Cites] Nat Rev Cancer. 2005 Jan;5(1):29-41 [15630413.001]

[Cites] Oncogene. 2004 Sep 30;23(45):7527-36 [15326483.001]

(PMID = 16651632.001).

[ISSN] 0002-9440

[Journal-full-title] The American journal of pathology

[ISO-abbreviation] Am. J. Pathol.

[Language] eng

[Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers; 0 / Galectin 1; 0 / Galectin 3; 0 / LGALS1 protein, human

[Other-IDs] NLM/ PMC1606586

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

To this end, we implement a memetic algorithm for the problem and demonstrate the effectiveness of the arithmetic-harmonic cut on a number of datasets including a cancer type dataset and a corona virus dataset.

[MeSH-minor] Algorithms. Cell Line, Tumor. Cluster Analysis. Colonic Neoplasms / metabolism. Gene Expression Profiling. Humans. Leukemia / metabolism. Melanoma / metabolism. Models, Statistical. Models, Theoretical

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Genet. 2000 Mar;24(3):227-35 [10700174.001]

[Cites] Evol Comput. 2000 Spring;8(1):61-91 [10753231.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4465-70 [11904358.001]

[Cites] IEEE Trans Pattern Anal Mach Intell. 2007 Nov;29(11):1944-57 [17848776.001]

[Cites] Bioinformatics. 2004 Jun 12;20(9):1453-4 [14871861.001]

[Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]

[Cites] BMC Bioinformatics. 2003 Sep 20;4:43 [14499005.001]

(PMID = 21151943.001).

[ISSN] 1932-6203

[Journal-full-title] PloS one

[ISO-abbreviation] PLoS ONE

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Other-IDs] NLM/ PMC2997101

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: We have evaluated five real-time ARMS assays: BRAF 1799T>A, [this includes V600E and V600K] and NRAS 182A>G [Q61R] and 181C>A [Q61K] in melanoma, EGFR 2573T>G [L858R], 2235-2249del15 [E746-A750del] in non-small-cell lung cancer, and compared the results to DNA sequencing of the mutation 'hot-spots' in these genes in formalin-fixed paraffin-embedded tumour (FF-PET) DNA.

[MeSH-minor] Carcinoma, Non-Small-Cell Lung / genetics. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Humans. Lung Neoplasms / genetics. Melanoma / genetics. Skin Neoplasms / genetics

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nucleic Acids Res. 1989 Apr 11;17(7):2503-16 [2785681.001]

[Cites] Hum Mutat. 2004 Apr;23(4):368-78 [15024731.001]

[Cites] Anal Biochem. 1997 Feb 15;245(2):207-12 [9056213.001]

[Cites] Br J Cancer. 1998 Apr;77(8):1267-74 [9579832.001]

[Cites] Clin Chem. 1998 May;44(5):918-23 [9590362.001]

[Cites] Nucleic Acids Res. 1999 Aug 15;27(16):e12 [10454649.001]

[Cites] J Mol Diagn. 2005 Aug;7(3):413-21 [16049314.001]

[Cites] Clin Chem. 2006 Apr;52(4):557-8 [16595822.001]

[Cites] Cancer Sci. 2006 Jul;97(7):642-8 [16827805.001]

[Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]

[Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]

[Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]

[Cites] Chest. 2007 Jun;131(6):1628-34 [17565015.001]

[Cites] Br J Cancer. 2007 Sep 17;97(6):778-84 [17848912.001]

[Cites] Clin Chem. 2008 Apr;54(4):757-60 [18375489.001]

[Cites] Cancer Sci. 2008 May;99(5):929-35 [18325048.001]

[Cites] Nat Med. 2008 May;14(5):579-84 [18408729.001]

[Cites] Eur Respir J. 2009 Jun;33(6):1485-97 [19483050.001]

[Cites] Br J Cancer. 2009 Nov 17;101(10):1724-30 [19861964.001]

[Cites] Nat Rev Drug Discov. 2010 May;9(5):363-6 [20431568.001]

[Cites] Mol Med. 2002 May;8(5):227-37 [12359953.001]

[Cites] Pathol Res Pract. 1993 Feb;189(1):66-72 [8390645.001]

(PMID = 20925915.001).

[ISSN] 1756-9966

[Journal-full-title] Journal of experimental & clinical cancer research : CR

[ISO-abbreviation] J. Exp. Clin. Cancer Res.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / DNA, Neoplasm

[Other-IDs] NLM/ PMC2988723

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Samples of isolated DNA and exosome fractions from human ovarian (2008) and melanoma (T289) cancer cell lines were used.

[MeSH-minor] Cell Line, Tumor. Female. Humans. Mass Spectrometry. Melanoma / metabolism. Ovarian Neoplasms / metabolism. Sensitivity and Specificity. Subcellular Fractions

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

Hazardous Substances Data Bank. PLATINUM .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17286953.001).

[ISSN] 0003-2697

[Journal-full-title] Analytical biochemistry

[ISO-abbreviation] Anal. Biochem.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Adducts; 0 / DNA, Neoplasm; 0 / Organoplatinum Compounds; 49DFR088MY / Platinum; Q20Q21Q62J / Cisplatin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Although melanoma is one of the most aggressive tumours, early detection and a high rate of diagnostic accuracy, followed by timely excision, can allow complete recovery in melanoma patients.

This result is important for screening, as it can inform the decision to excise precociously malignant lesions or to avoid unnecessary removal of benign ones.

[MeSH-major] Fractals. Image Processing, Computer-Assisted / methods. Melanoma / diagnosis. Skin Diseases / diagnosis

[MeSH-minor] Diagnosis, Differential. Humans. Nevus, Pigmented / diagnosis. Nevus, Pigmented / pathology

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Conditions.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Mech Ageing Dev. 2001 Sep 15;122(13):1461-75 [11470133.001]

[Cites] Gynecol Oncol. 1999 Oct;75(1):78-83 [10502430.001]

[Cites] Pathologica. 1995 Jun;87(3):310-7 [8570291.001]

[Cites] Med Image Anal. 2003 Mar;7(1):47-64 [12467721.001]

[Cites] Am J Dermatopathol. 1995 Aug;17(4):374-8 [8600802.001]

[Cites] Curr Eye Res. 1993 Jan;12(1):23-7 [8436007.001]

[Cites] Arch Dermatol. 1998 Dec;134(12):1563-70 [9875194.001]

[Cites] Br J Dermatol. 2002 Sep;147(3):481-6 [12207587.001]

[Cites] IEEE Trans Med Imaging. 2003 Aug;22(8):959-64 [12906250.001]

[Cites] Mod Pathol. 1996 Mar;9(3):174-82 [8685210.001]

[Cites] Cancer Res. 2000 Jul 15;60(14 ):3683-8 [10919633.001]

[Cites] J Telemed Telecare. 2000;6(3):132-7 [10912329.001]

[Cites] J Pathol. 1992 Apr;166(4):409-11 [1517895.001]

[Cites] J Biomed Eng. 1992 May;14(3):229-34 [1588780.001]

[Cites] Neurobiol Aging. 2002 Jan-Feb;23(1):23-6 [11755014.001]

[Cites] J Am Acad Dermatol. 2003 May;48(5):679-93 [12734496.001]

[Cites] Skin Res Technol. 1995 Nov;1(4):187-91 [27326721.001]

[Cites] Cancer. 1987 Mar 15;59(6):1236-41 [3815299.001]

[Cites] J Pathol. 1995 Sep;177(1):103-7 [7472773.001]

[Cites] Arch Dermatol. 1993 Feb;129(2):157-74 [8434973.001]

[Cites] Eur J Dermatol. 2001 May-Jun;11(3):270-6; quiz 277 [11358742.001]

[Cites] J Pathol. 1997 May;182(1):1-8 [9227334.001]

[Cites] Philos Trans R Soc Lond B Biol Sci. 2002 May 29;357(1421):619-26 [12079523.001]

[Cites] Riv Biol. 2002 May-Aug;95(2):239-58 [12449683.001]

(PMID = 16255424.001).

[ISSN] 0140-0118

[Journal-full-title] Medical & biological engineering & computing

[ISO-abbreviation] Med Biol Eng Comput

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Wide local excision could be considered as the initial treatment of primary anorectal malignant melanoma.

BACKGROUND: Anorectal malignant melanoma was a rare disease with extremely poor prognosis.

The aim of this study was to explore the clinical characteristic, diagnosis and treatment strategies of anorectal malignant melanoma.

METHODS: The data of 57 patients with anorectal malignant melanoma was collected and retrospectively analyzed.

RESULTS: Rectal bleeding and anal mass were found to be common symptoms of anorectal malignant melanoma.

The preoperative diagnosis rate of anorectal malignant melanoma was 48.6%.

CONCLUSIONS: This study identified no survival advantage to abdominoperineal resection in treatment of anorectal malignant melanoma, and we propose that wide local excision could be considered as the initial treatment of choice.

[MeSH-major] Anus Neoplasms / surgery. Melanoma / surgery

MedlinePlus Health Information. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Melanoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20367986.001).

[ISSN] 0366-6999

[Journal-full-title] Chinese medical journal

[ISO-abbreviation] Chin. Med. J.

[Language] eng

[Publication-type] Journal Article

[Publication-country] China

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Osteopontin expression in normal skin and non-melanoma skin tumors.

Osteopontin (OPN) is an adhesive, matricellular glycoprotein, whose expression is elevated in many types of cancer and has been shown to facilitate tumorigenesis in vivo.

To understand the role of OPN in human skin cancer, this study is designed to determine whether OPN is expressed in premalignant [solar/actinic keratosis (AK)] and in malignant skin lesions such as squamous cell carcinomas (SCC) and basal cell carcinomas (BCC), as well as in normal skin exposed or not exposed to sunlight.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Exp Cell Res. 1995 Feb;216(2):335-41 [7843278.001]

[Cites] Am J Pathol. 1995 Jan;146(1):95-100 [7856741.001]

[Cites] Arch Dermatol. 1995 Jul;131(7):796-800 [7611795.001]

[Cites] Matrix Biol. 1995 Jul;14(7):553-60 [8535605.001]

[Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]

[Cites] Lung Cancer. 1996 Nov;15(3):311-23 [8959677.001]

[Cites] Arch Biochem Biophys. 1997 Jul 15;343(2):157-63 [9224725.001]

[Cites] Cancer Invest. 1998;16(5):329-44 [9627681.001]

[Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):136-42 [9627707.001]

[Cites] J Bone Miner Res. 1998 Jul;13(7):1101-11 [9661074.001]

[Cites] Clin Cancer Res. 1997 Apr;3(4):605-11 [9815727.001]

[Cites] Curr Opin Cell Biol. 1998 Oct;10(5):640-6 [9818175.001]

[Cites] Hum Pathol. 1998 Nov;29(11):1250-4 [9824103.001]

[Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1087-90 [9870857.001]

[Cites] Invest Ophthalmol Vis Sci. 2006 Mar;47(3):802-6 [16505010.001]

[Cites] J Pediatr Surg. 2006 Apr;41(4):624-32; discussion 624-32 [16567167.001]

[Cites] Am J Pathol. 2006 Jul;169(1):233-46 [16816376.001]

[Cites] Arch Dermatol. 2006 Jul;142(7):900-6 [16847207.001]

[Cites] Cancer Res. 2006 Jul 15;66(14):7119-27 [16849558.001]

[Cites] Zhonghua Wei Chang Wai Ke Za Zhi. 2007 Jan;10(1):73-6 [17253181.001]

[Cites] J Histochem Cytochem. 2007 Apr;55(4):403-9 [17210923.001]

[Cites] Pathol Res Pract. 1999;195(11):733-9 [10605692.001]

[Cites] Br J Cancer. 2000 Jul;83(2):156-63 [10901364.001]

[Cites] Biochem Biophys Res Commun. 2001 Jan 19;280(2):460-5 [11162539.001]

[Cites] Clin Cancer Res. 2001 Dec;7(12):4060-6 [11751502.001]

[Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):270-8 [11807984.001]

[Cites] J Invest Dermatol. 2001 Dec;117(6):1554-8 [11886522.001]

[Cites] J Oral Pathol Med. 1999 Mar;28(3):97-101 [10069535.001]

[Cites] Clin Cancer Res. 1999 Aug;5(8):2271-7 [10473115.001]

[Cites] Am J Respir Crit Care Med. 1999 Oct;160(4):1269-73 [10508818.001]

[Cites] Dent Mater J. 2004 Dec;23(4):650-5 [15688734.001]

[Cites] Cancer Res. 2005 May 1;65(9):3958-65 [15867397.001]

[Cites] Kidney Int. 2005 Jul;68(1):155-66 [15954904.001]

[Cites] Trends Cell Biol. 2006 Feb;16(2):79-87 [16406521.001]

[Cites] Int J Cancer. 2006 May 1;118(9):2255-61 [16331611.001]

[Cites] Exp Cell Res. 2007 Apr 1;313(6):1149-60 [17306792.001]

[Cites] Oncogene. 2007 May 3;26(20):2840-50 [17160024.001]

[Cites] Bone. 2007 Jun;40(6):1517-28 [17395559.001]

[Cites] Diabetes. 2007 Jun;56(6):1662-70 [17360982.001]

[Cites] Clin Exp Metastasis. 2003;20(1):77-84 [12650610.001]

[Cites] Cancer. 2003 Jul 1;98(1):119-27 [12833464.001]

[Cites] Protein Expr Purif. 2003 Aug;30(2):238-45 [12880773.001]

[Cites] Carcinogenesis. 2003 Nov;24(11):1749-58 [12919959.001]

[Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90 [14734468.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):487-91 [15006928.001]

[Cites] Br J Cancer. 2004 May 17;90(10):1877-81 [15138464.001]

[Cites] J Dent Res. 2004 Sep;83(9):664-70 [15329369.001]

[Cites] J Surg Res. 2004 Oct;121(2):228-41 [15501463.001]

[Cites] Proc Natl Acad Sci U S A. 1986 Oct;83(19):7182-6 [3532105.001]

[Cites] J Biol Chem. 1987 Feb 25;262(6):2900-7 [3469201.001]

[Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]

[Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]

[Cites] J Exp Med. 1989 Jul 1;170(1):145-61 [2787378.001]

[Cites] Genomics. 1989 Aug;5(2):375-7 [2571582.001]

[Cites] Anticancer Res. 1989 Sep-Oct;9(5):1291-9 [2686530.001]

[Cites] Genomics. 1990 Aug;7(4):491-502 [1974876.001]

[Cites] Cancer Res. 1991 Apr 15;51(8):2144-50 [2009532.001]

[Cites] Mol Carcinog. 1991;4(3):196-202 [2064725.001]

[Cites] J Bone Miner Res. 1992 Jul;7(7):743-54 [1642143.001]

[Cites] Mol Biol Cell. 1992 Oct;3(10):1169-80 [1421573.001]

[Cites] J Histochem Cytochem. 1994 Mar;42(3):351-61 [8308252.001]

[Cites] Endocrinology. 1994 Sep;135(3):863-9 [8070379.001]

[Cites] Am J Pathol. 1994 Sep;145(3):610-23 [8080043.001]

[Cites] Cancer. 1995 Jan 15;75(2 Suppl):607-12 [7804986.001]

[Cites] Lab Invest. 1995 Jan;72(1):55-63 [7837791.001]

[Cites] Lab Invest. 1995 Jan;72(1):64-9 [7837792.001]

[Cites] Cell Growth Differ. 1997 Oct;8(10):1061-9 [9342184.001]

[Cites] J Cell Biochem. 1997 Dec 1;67(3):386-96 [9361193.001]

[Cites] J Clin Invest. 1998 Apr 1;101(7):1468-78 [9525990.001]

[Cites] Int J Cancer. 1998 Apr 17;79(2):127-32 [9583725.001]

[Cites] J Biol Chem. 1994 Sep 16;269(37):23280-5 [8083234.001]

[Cites] JAMA. 2002 Apr 3;287(13):1671-9 [11926891.001]

[Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):513-21 [11929952.001]

[Cites] J Am Soc Nephrol. 2002 May;13(5):1210-8 [11961008.001]

[Cites] Cancer. 2002 Aug 1;95(3):506-12 [12209742.001]

(PMID = 17938278.001).

[ISSN] 0022-1554

[Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society

[ISO-abbreviation] J. Histochem. Cytochem.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA090920; United States / NCI NIH HHS / CA / R01 CA90920

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 106441-73-0 / Osteopontin

[Other-IDs] NLM/ PMC2323122

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Other approaches include a polyhemoglobin-fibrinogen that acts as an oxygen carrier with platelet-like activity, and a polyhemoglobin-tyrosinase to retard the growth of a fatal skin cancer, melanoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Biochem. 2002 Apr;131(4):611-7 [11927000.001]

[Cites] Artif Cells Blood Substit Immobil Biotechnol. 2007;35(5):481-9 [17922313.001]

[Cites] J Am Coll Surg. 2002 Oct;195(4):445-52; discussion 452-5 [12375748.001]

[Cites] Nat Rev Drug Discov. 2004 Feb;3(2):152-9 [15043006.001]

[Cites] Melanoma Res. 2004 Jun;14(3):197-202 [15179188.001]

[Cites] Anal Biochem. 1971 Apr;40(2):450-8 [5551554.001]

[Cites] Biochem Biophys Res Commun. 1971 Sep 17;44(6):1531-6 [5160711.001]

[Cites] J Bioeng. 1976 Nov;1(1):25-32 [1052520.001]

[Cites] Exp Hematol. 1980 May;8(5):584-92 [7461058.001]

[Cites] Methods Enzymol. 1985;112:195-203 [4046849.001]

[Cites] Trends Biochem Sci. 1989 Feb;14(2):42-4 [2650040.001]

[Cites] Biomater Artif Cells Immobilization Biotechnol. 1993;21(5):609-21 [8117850.001]

[Cites] Artif Cells Blood Substit Immobil Biotechnol. 1994;22(3):889-93 [7994414.001]

[Cites] Artif Cells Blood Substit Immobil Biotechnol. 1996 May;24(3):169-83 [8773737.001]

[Cites] Nat Biotechnol. 1998 Jul;16(7):667-71 [9661202.001]

[Cites] J Pharmacol Exp Ther. 1999 Feb;288(2):665-70 [9918573.001]

[Cites] Science. 1964 Oct 23;146(3643):524-5 [14190240.001]

[Cites] Artif Cells Blood Substit Immobil Biotechnol. 2007;35(1):11-8 [17364467.001]

[Cites] Artif Cells Blood Substit Immobil Biotechnol. 2007;35(1):31-43 [17364469.001]

[Cites] Artif Cells Blood Substit Immobil Biotechnol. 2002 Jan;30(1):23-37 [12000224.001]

(PMID = 18565337.001).

[ISSN] 0006-3002

[Journal-full-title] Biochimica et biophysica acta

[ISO-abbreviation] Biochim. Biophys. Acta

[Language] ENG

[Grant] None / None / / 13745; Canada / Canadian Institutes of Health Research / / 13745

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Blood Substitutes; 0 / Cross-Linking Reagents; 0 / Hemoglobins; 0 / Oxyhemoglobins; 0 / polyhemoglobin; 9001-32-5 / Fibrinogen; 9034-51-9 / Hemoglobin A; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase

[Other-IDs] NLM/ CAMS2513; NLM/ PMC3514548

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma.

Melanoma and other cancers harbor oncogenic mutations in the protein kinase B-Raf, which leads to constitutive activation and dysregulation of MAP kinase signaling.

In order to elucidate molecular determinants responsible for B-Raf control of cancer phenotypes, we present a method for phosphoprotein profiling, using negative ionization mass spectrometry to detect phosphopeptides based on their fragment ion signature caused by release of PO(3)(-).

Ninety phosphorylation events were regulated by oncogenic B-Raf signaling, based on their responses to treating melanoma cells with MKK1/2 inhibitor.

We investigated MINERVA/FAM129B, a target belonging to a protein family with unknown category and function, and established the importance of this protein and its MAP kinase-dependent phosphorylation in controlling melanoma cell invasion into three-dimensional collagen matrix.

MedlinePlus Health Information. consumer health - Melanoma.

COS Scholar Universe. author profiles.

PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

SciCrunch. HGNC: Data: Gene Annotation .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Anal Chem. 2004 Jul 1;76(13):3556-68 [15228325.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12130-5 [15302935.001]

[Cites] J Biol Chem. 1989 Dec 5;264(34):20518-25 [2511205.001]

[Cites] Biochem J. 1994 Nov 1;303 ( Pt 3):701-4 [7980435.001]

[Cites] Anal Biochem. 1996 Aug 1;239(2):180-92 [8811904.001]

[Cites] EMBO J. 1997 Nov 3;16(21):6439-51 [9351826.001]

[Cites] J Biol Chem. 1998 Jan 16;273(3):1496-505 [9430688.001]

[Cites] Nat Struct Mol Biol. 2004 Dec;11(12):1192-7 [15543157.001]

[Cites] Oncogene. 2005 May 12;24(21):3459-71 [15735667.001]

[Cites] J Cell Biol. 2005 Aug 29;170(5):703-8 [16129781.001]

[Cites] Mol Cell Proteomics. 2005 Sep;4(9):1240-50 [15951569.001]

[Cites] Mol Cell Proteomics. 2005 Oct;4(10):1487-502 [15979981.001]

[Cites] J Exp Med. 2006 Jul 10;203(7):1651-6 [16801397.001]

[Cites] J Clin Oncol. 2006 Sep 10;24(26):4340-6 [16908931.001]

[Cites] Nat Biotechnol. 2006 Oct;24(10):1285-92 [16964243.001]

[Cites] Cell. 2006 Nov 3;127(3):635-48 [17081983.001]

[Cites] Mol Cell Proteomics. 2007 Jan;6(1):1-17 [17018520.001]

[Cites] Curr Biol. 2007 Jan 23;17(2):179-84 [17174095.001]

[Cites] Nature. 2007 Feb 22;445(7130):851-7 [17314971.001]

[Cites] Nat Methods. 2007 Mar;4(3):231-7 [17293869.001]

[Cites] Cancer Res. 2003 Feb 15;63(4):756-9 [12591721.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):183-8 [12518064.001]

[Cites] Cancer Res. 2002 Dec 1;62(23):6997-7000 [12460918.001]

[Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]

[Cites] Rapid Commun Mass Spectrom. 2001;15(17):1593-9 [11544598.001]

[Cites] Anal Chem. 2001 Apr 1;73(7):1440-8 [11321292.001]

[Cites] Methods Enzymol. 2001;332:417-31 [11305115.001]

[Cites] EMBO J. 2000 Jun 15;19(12):2924-34 [10856237.001]

[Cites] Mol Cancer Ther. 2006 May;5(5):1136-44 [16731745.001]

[Cites] Proteomics. 2004 Jun;4(6):1551-61 [15174125.001]

[Cites] Mol Cell Biol. 2004 Jun;24(12):5269-80 [15169891.001]

[Cites] Cell. 2004 Mar 19;116(6):855-67 [15035987.001]

[Cites] Mol Cell Biol. 2004 Apr;24(7):2923-31 [15024080.001]

[Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]

[Cites] Biochem J. 2004 Jan 1;377(Pt 1):249-55 [14570592.001]

[Cites] Leukemia. 2003 Aug;17(8):1605-12 [12886250.001]

[Cites] Cancer Res. 2003 Jul 15;63(14):3955-7 [12873990.001]

[Cites] Anal Chem. 2003 Apr 15;75(8):1895-904 [12713048.001]

[Cites] Cancer Lett. 2008 Jul 8;265(2):157-66 [18406052.001]

[Cites] Mol Cell Proteomics. 2006 Feb;5(2):337-46 [16260767.001]

[Cites] Cancer Res. 2007 Apr 1;67(7):3177-84 [17409425.001]

[Cites] Clin Cancer Res. 2007 Aug 15;13(16):4934-42 [17652623.001]

[Cites] Nat Chem Biol. 2005 Oct;1(5):252-62 [16408053.001]

[CommentIn] Mol Cell. 2009 Apr 24;34(2):139-40 [19394291.001]

(PMID = 19362540.001).

[ISSN] 1097-4164

[Journal-full-title] Molecular cell

[ISO-abbreviation] Mol. Cell

[Language] ENG

[Grant] United States / NCRR NIH HHS / RR / RR021005-01; United States / NIGMS NIH HHS / GM / GM065103-08; United States / NCI NIH HHS / CA / R01-CA126240; United States / NIGMS NIH HHS / GM / T32 GM008759; United States / NCI NIH HHS / CA / R01-CA118972; United States / NIGMS NIH HHS / GM / T32 GM065103-08; United States / NCRR NIH HHS / RR / S10 RR021005-01; United States / NCI NIH HHS / CA / R01 CA118972; United States / NCI NIH HHS / CA / R01 CA118972-02; United States / NCI NIH HHS / CA / R01 CA126240; United States / NCRR NIH HHS / RR / S10 RR021005; United States / NIGMS NIH HHS / GM / T32 GM065103

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Fam129B protein, human; 0 / Phosphoproteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf

[Other-IDs] NLM/ NIHMS111623; NLM/ PMC2735263

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Using this tool, individual carbon nanotubes, gold nanorods, and melanoma cells with intrinsic melanin markers were identified in unstained (e.g. sentinel lymph nodes) and conventionally-stained tissues.

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. GOLD, ELEMENTAL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] © 2010 International Society for Advancement of Cytometry.

[Cites] BMC Cell Biol. 2007;8 Suppl 1:S8 [17634098.001]

[Cites] Magn Reson Med. 2007 May;57(5):835-41 [17457873.001]

[Cites] Biosens Bioelectron. 2007 Nov 30;23(4):449-58 [17881213.001]

[Cites] Clin Chem. 2007 Nov;53(11):2002-9 [17890442.001]

[Cites] Small. 2008 Jan;4(1):153-9 [18081130.001]

[Cites] J Toxicol Sci. 2008 Feb;33(1):105-16 [18303189.001]

[Cites] Mol Pharm. 2008 Mar-Apr;5(2):316-27 [18217714.001]

[Cites] Environ Sci Technol. 2008 Aug 15;42(16):6264-70 [18767697.001]

[Cites] Cytometry A. 2008 Oct;73(10):884-94 [18677768.001]

[Cites] Nano Lett. 2008 Nov;8(11):3953-8 [18834183.001]

[Cites] Analyst. 2009 Mar;134(3):425-39 [19238274.001]

[Cites] Cytometry A. 2009 Apr;75(4):282-8 [19012320.001]

[Cites] J Biophotonics. 2009 Feb;2(1-2):91-103 [19343688.001]

[Cites] Nano Lett. 2009 Mar;9(3):1023-7 [19199447.001]

[Cites] Clin Chim Acta. 2009 May;403(1-2):1-8 [19361470.001]

[Cites] J Biomed Opt. 2009 Mar-Apr;14(2):021017 [19405730.001]

[Cites] J Biomech Eng. 2009 Jul;131(7):074519 [19640155.001]

[Cites] Ultrastruct Pathol. 2009 Jul-Aug;33(4):155-9 [19728231.001]

[Cites] J Biophotonics. 2009 Sep;2(8-9):528-39 [19743443.001]

[Cites] Photosynth Res. 2009 Aug-Sep;101(2-3):245-66 [19714478.001]

[Cites] Nat Nanotechnol. 2009 Oct;4(10):688-94 [19809462.001]

[Cites] Cancer Res. 2009 Oct 15;69(20):7926-34 [19826056.001]

[Cites] J Mass Spectrom. 2009 Oct;44(10):1417-22 [19753579.001]

[Cites] Nature. 2009 Oct 22;461(7267):1105-9 [19847261.001]

[Cites] J R Soc Interface. 2010 Jan 6;7(42):49-59 [19324670.001]

[Cites] Nat Nanotechnol. 2009 Dec;4(12):855-60 [19915570.001]

[Cites] Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 Jul-Aug;1(4):353-9 [20049802.001]

[Cites] Mol Biosyst. 2010 Apr;6(4):641-7 [20237641.001]

[Cites] Radiology. 2010 May;255(2):442-50 [20413757.001]

[Cites] Chem Rev. 2010 May 12;110(5):2783-94 [20387910.001]

[Cites] Opt Express. 2010 Apr 12;18(8):8605-20 [20588705.001]

[Cites] Opt Express. 2010 Jul 5;18(14):14375-84 [20639922.001]

[Cites] Nature. 2010 Jul 29;466(7306):647-51 [20613725.001]

[Cites] ACS Nano. 2010 Jul 27;4(7):3689-96 [20550178.001]

[Cites] J Biophotonics. 2010 Dec;3(12):791-806 [20572284.001]

[Cites] Arch Toxicol. 2011 Jul;85(7):723-31 [20499226.001]

[Cites] Opt Lett. 2003 Aug 1;28(15):1314-6 [12906074.001]

[Cites] Biophys J. 2006 Jan 15;90(2):619-27 [16239330.001]

[Cites] Phys Chem Chem Phys. 2006 Aug 14;8(30):3486-95 [16871337.001]

[Cites] Histopathology. 2006 Oct;49(4):411-24 [16978205.001]

[Cites] Environ Health Perspect. 2007 Mar;115(3):377-82 [17431486.001]

[Cites] Toxicol Sci. 2007 Nov;100(1):203-14 [17660506.001]

(PMID = 20949577.001).

[ISSN] 1552-4930

[Journal-full-title] Cytometry. Part A : the journal of the International Society for Analytical Cytology

[ISO-abbreviation] Cytometry A

[Language] ENG

[Grant] United States / NIBIB NIH HHS / EB / R01 EB009230-03; None / None / / R01 EB000873-01A2; United States / NCI NIH HHS / CA / R21 CA139373-01; United States / NIBIB NIH HHS / EB / R01 EB009230-01A1; United States / NIBIB NIH HHS / EB / R01 EB000873-04; None / None / / R01 EB000873-03; United States / NIBIB NIH HHS / EB / R01 EB000873-01A2; None / None / / R21 CA139373-02; United States / NIBIB NIH HHS / EB / R01 EB009230; None / None / / R01 EB009230-01A1; United States / NCI NIH HHS / CA / R01 CA131164-02; None / None / / R01 EB000873-04; United States / NIBIB NIH HHS / EB / R01 EB000873-02; United States / NIBIB NIH HHS / EB / R01 EB000873-03; None / None / / R01 CA131164-02; None / None / / R01 EB009230-03; United States / NCI NIH HHS / CA / R01 CA131164-04; None / None / / R01 EB009230-02; United States / NCI NIH HHS / CA / R01 CA131164-03; None / None / / R21 CA139373-01; United States / NCI NIH HHS / CA / R01CA131164; United States / NIBIB NIH HHS / EB / R01EB009230; None / None / / R01 CA131164-03; United States / NIBIB NIH HHS / EB / R01EB000873; United States / NIBIB NIH HHS / EB / R01 EB000873; United States / NCI NIH HHS / CA / R01 CA131164-01A2; None / None / / R01 EB000873-02; None / None / / R01 CA131164-01A2; United States / NCI NIH HHS / CA / R21 CA139373-02; United States / NIBIB NIH HHS / EB / R01 EB009230-02; United States / NCI NIH HHS / CA / R01 CA131164; None / None / / R01 CA131164-04; United States / NCI NIH HHS / CA / R21 CA139373; United States / NCI NIH HHS / CA / R21CA139373

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Melanins; 0 / Nanotubes, Carbon; 7440-57-5 / Gold

[Other-IDs] NLM/ NIHMS268710; NLM/ PMC3339495

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Chemosorption of radiometals of interest to nuclear medicine by synthetic melanins.

INTRODUCTION: Melanins are high-molecular-weight pigments that are ubiquitous in nature and can also be synthesized in the laboratory from a variety of precursors.

Melanins possess numerous interesting physicochemical characteristics, including electromagnetic radiation absorption properties and ability to chelate metals.

We have recently reported that melanin has remarkable ionizing-radiation-shielding properties, possibly because it can interact with photons via Compton scattering.

We hypothesized that, if administered internally, melanin could play a beneficial role by scavenging various radionuclides, in addition to radiation shielding.

METHODS: Three melanins were synthesized from dopamine, 3,4-dihydroxyphenylalanine (l-Dopa) and a combination of l-cysteine and l-Dopa.

For control, synthetic melanin made from tyrosine polymerization (Sigma) was used.

Melanins were characterized by elemental analysis.

The chemosorption of 111In, 225Ac and 213Bi by melanins was studied at 37 degrees C for up to 48 h.

RESULTS: The C-to-N molar ratios for dopamine, l-Dopa and tyrosine melanins were very close at 7.92, 8.39 and 8.48, respectively, while in mixed l-cysteine/l-Dopa melanin, that ratio was much lower at 3.63.

This mixed melanin also contained 22.33% sulfur, thus confirming incorporation of S-containing motifs into its structure.

Dopamine, l-Dopa and tyrosine melanins were very similar in their abilities to decrease the activity of 111In, 225Ac and 213Bi and their radioactive daughters in supernatants by >10-fold in comparison with the starting levels, while mixed l-cysteine/l-Dopa melanin was able to chemosorb only 111In.

CONCLUSIONS: We have demonstrated that synthetic melanins made of diverse precursors can chemosorb 111In, 213Bi and 225Ac, with dopamine, l-Dopa and tyrosine melanins being the most efficient towards all three of these radionuclides.

Such properties of synthetic melanins can contribute to the development of the novel melanin-based radioprotective materials.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. DOPAMINE .

Hazardous Substances Data Bank. CYSTEINE .

Hazardous Substances Data Bank. L-TYROSINE .

Hazardous Substances Data Bank. BISMUTH, ELEMENTAL .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] FEMS Microbiol Lett. 2003 Mar 14;220(1):99-104 [12644234.001]

[Cites] Anal Biochem. 1985 Feb 1;144(2):527-36 [3993914.001]

[Cites] Bioessays. 1992 Jan;14(1):49-56 [1546980.001]

[Cites] Infect Immun. 1996 Jul;64(7):2420-4 [8698461.001]

[Cites] Pigment Cell Melanoma Res. 2008 Apr;21(2):192-9 [18426412.001]

[Cites] Pigment Cell Res. 2006 Dec;19(6):572-94 [17083485.001]

[Cites] PLoS One. 2007;2(5):e457 [17520016.001]

[Cites] J Phys Chem B. 2007 Jul 19;111(28):7938-47 [17580858.001]

[Cites] Appl Radiat Isot. 2005 May;62(5):667-79 [15763472.001]

(PMID = 18355691.001).

[ISSN] 0969-8051

[Journal-full-title] Nuclear medicine and biology

[ISO-abbreviation] Nucl. Med. Biol.

[Language] ENG

[Grant] United States / NIAID NIH HHS / AI / AI52733; United States / NIAID NIH HHS / AI / AI060507-04; United States / NIAID NIH HHS / AI / R01 AI060507-03; United States / NIAID NIH HHS / AI / R01 AI060507-03S1; United States / NIAID NIH HHS / AI / AI60507; United States / NIAID NIH HHS / AI / R01 AI052733; United States / NIAID NIH HHS / AI / R56 AI060507; United States / Howard Hughes Medical Institute / / ; United States / NIAID NIH HHS / AI / AI060507-03S1; United States / NIAID NIH HHS / AI / R01 AI060507; United States / NIAID NIH HHS / AI / AI060507-03; United States / NIAID NIH HHS / AI / R01 AI060507-04

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Indium Radioisotopes; 0 / Melanins; 42HK56048U / Tyrosine; 46627O600J / Levodopa; K848JZ4886 / Cysteine; NIK1K0956U / Actinium; U015TT5I8H / Bismuth; VTD58H1Z2X / Dopamine

[Other-IDs] NLM/ NIHMS47415; NLM/ PMC2516407

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anatomical and molecular imaging of skin cancer.

Skin cancer is the most common form of cancer types.

It is generally divided into two categories: melanoma (∼ 5%) and nonmelanoma (∼ 95%), which can be further categorized into basal cell carcinoma, squamous cell carcinoma, and some rare skin cancer types.

Biopsy is still the gold standard for skin cancer evaluation in the clinic.

Various anatomical imaging techniques have been used to evaluate different types of skin cancer lesions, including laser scanning confocal microscopy, optical coherence tomography, high-frequency ultrasound, terahertz pulsed imaging, magnetic resonance imaging, and some other recently developed techniques such as photoacoustic microscopy.

However, anatomical imaging alone may not be sufficient in guiding skin cancer diagnosis and therapy.

Over the last decade, various molecular imaging techniques (in particular single photon emission computed tomography and positron emission tomography) have been investigated for skin cancer imaging.

The pathways or molecular targets that have been studied include glucose metabolism, integrin α(v)β(3), melanocortin-1 receptor, high molecular weight melanoma-associated antigen, and several other molecular markers.

It is likely that this situation will change in the near future and molecular imaging will truly play an important role in personalized medicine of melanoma patients.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Z Arztl Fortbild Qualitatssich. 1997 Jul;91(4):347-53 [9340205.001]

[Cites] Radiographics. 1997 Nov-Dec;17(6):1559-65 [9397463.001]

[Cites] J Clin Oncol. 1998 May;16(5):1770-6 [9586890.001]

[Cites] NMR Biomed. 2008 Mar;21(3):296-300 [18246539.001]

[Cites] J Biomed Opt. 2008 Jan-Feb;13(1):014003 [18315361.001]

[Cites] Adv Exp Med Biol. 2008;624:215-26 [18348459.001]

[Cites] Adv Exp Med Biol. 2008;624:227-40 [18348460.001]

[Cites] Adv Exp Med Biol. 2008;624:296-318 [18348465.001]

[Cites] J Biomed Opt. 2008 Mar-Apr;13(2):024013 [18465976.001]

[Cites] J Nucl Med. 2008 Jun;49 Suppl 2:113S-28S [18523069.001]

[Cites] Opt Express. 2002 Jul 29;10(15):707-13 [19451924.001]

[Cites] Biotechniques. 2005 Dec;39(6 Suppl):S6-13 [20158503.001]

[Cites] J Nucl Med. 1990 Nov;31(11):1831-5 [2230996.001]

[Cites] Ann Surg. 1986 Sep;204(3):223-35 [3753057.001]

[Cites] Science. 1994 Apr 22;264(5158):569-71 [7512751.001]

[Cites] Annu Rev Cell Dev Biol. 1996;12:697-715 [8970741.001]

[Cites] Dermatol Surg. 1997 Jan;23(1):43-5 [9107293.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):12814-8 [9788997.001]

[Cites] Am J Pathol. 1998 Nov;153(5):1347-51 [9811323.001]

[Cites] AJR Am J Roentgenol. 1999 Feb;172(2):457-61 [9930803.001]

[Cites] Nucl Med Biol. 1999 Aug;26(6):687-93 [10587108.001]

[Cites] Crit Rev Oncog. 2000;11(2):147-63 [11005510.001]

[Cites] Cancer Res. 2000 Oct 15;60(20):5649-58 [11059756.001]

[Cites] Cancer Res. 2001 Jun 1;61(11):4474-82 [11389078.001]

[Cites] Nucl Med Biol. 2001 Jul;28(5):493-8 [11516693.001]

[Cites] J Nucl Med. 2001 Dec;42(12):1847-55 [11752084.001]

[Cites] Nucl Med Biol. 2006 Aug;33(6):723-33 [16934691.001]

[Cites] Ann Surg Oncol. 2007 Feb;14(2):913-21 [17146742.001]

[Cites] Br J Dermatol. 2007 Jan;156(1):81-4 [17199571.001]

[Cites] J Nucl Med. 2007 Jan;48(1):64-72 [17204700.001]

[Cites] J Nucl Med. 2007 Jan;48(1):73-80 [17204701.001]

[Cites] Cancer Imaging. 2006;6:204-8 [17208677.001]

[Cites] Bull Cancer. 2007 Jan;94(1):93-8 [17237009.001]

[Cites] J Nucl Med. 2007 Feb;48(2):304-10 [17268029.001]

[Cites] J Nucl Med. 2007 Mar;48(3):429-36 [17332621.001]

[Cites] Bioconjug Chem. 2007 May-Jun;18(3):765-72 [17348700.001]

[Cites] Dermatol Surg. 2007 Apr;33(4):421-5; discussion 425-6 [17430375.001]

[Cites] Front Biosci. 2007;12:4514-24 [17485393.001]

[Cites] Rofo. 2007 Jun;179(6):618-26 [17492539.001]

[Cites] Nucl Med Biol. 2007 May;34(4):363-70 [17499725.001]

[Cites] J Nucl Med. 2007 Jun;48(6):987-94 [17504880.001]

[Cites] Surg Oncol Clin N Am. 2007 Apr;16(2):403-30 [17560520.001]

[Cites] J Am Acad Dermatol. 2007 Oct;57(4):629-37 [17610989.001]

[Cites] J Biomed Opt. 2007 May-Jun;12(3):034027 [17614735.001]

[Cites] Arch Dermatol. 2007 Jul;143(7):883-6 [17638732.001]

[Cites] Cancer Biother Radiopharm. 2007 Jun;22(3):333-41 [17651039.001]

[Cites] Cutis. 2007 Mar;79(3):241-8 [17674590.001]

[Cites] Dermatol Surg. 2007 Oct;33(10):1158-74 [17903149.001]

[Cites] Dermatol Surg. 2007 Oct;33(10):1220-7; discussion 1226-7 [17903155.001]

[Cites] J Radiol. 1998 Apr;79(4):313-7 [9757255.001]

[Cites] Eur J Nucl Med. 1998 Oct;25(10):1383-9 [9818277.001]

[Cites] Bioconjug Chem. 2006 May-Jun;17(3):662-9 [16704203.001]

[Cites] J Dermatol Sci. 2006 Aug;43(2):135-41 [16806842.001]

[Cites] J Am Acad Dermatol. 2006 Sep;55(3):408-12 [16908344.001]

[Cites] J Nucl Med. 1999 Apr;40(4):591-603 [10210218.001]

[Cites] Cancer Res. 1999 Jun 15;59(12):2917-23 [10383155.001]

[Cites] Cancer Chemother Pharmacol. 1999;44(4):343-8 [10447583.001]

[Cites] J Nucl Med. 1999 Jun;40(6):1061-71 [10452325.001]

[Cites] J Am Acad Dermatol. 2000 Jul;43(1 Pt 1):42-8 [10863222.001]

[Cites] Neoplasia. 2000 Jan-Apr;2(1-2):9-25 [10933065.001]

[Cites] Cancer Res. 2001 Mar 1;61(5):1781-5 [11280722.001]

[Cites] J Clin Oncol. 2001 May 15;19(10):2674-8 [11352959.001]

[Cites] J Nucl Med. 2001 May;42(5 Suppl):1S-93S [11483694.001]

[Cites] Science. 2001 Oct 12;294(5541):339-45 [11546839.001]

[Cites] Hybrid Hybridomics. 2001;20(5-6):351-60 [11839253.001]

[Cites] Genes Dev. 2003 Mar 1;17(5):545-80 [12629038.001]

[Cites] Nat Rev Cancer. 2002 Feb;2(2):91-100 [12635172.001]

[Cites] Pigment Cell Res. 2003 Jun;16(3):266-72 [12753400.001]

[Cites] Oncogene. 2003 May 19;22(20):3172-9 [12789293.001]

[Cites] Lab Invest. 2003 Sep;83(9):1279-83 [13679435.001]

[Cites] Nat Biotechnol. 2003 Nov;21(11):1361-7 [14595364.001]

[Cites] Bioconjug Chem. 2003 Nov-Dec;14(6):1177-84 [14624632.001]

[Cites] Bioconjug Chem. 2004 Jan-Feb;15(1):61-9 [14733584.001]

[Cites] Cancer Res. 2004 Feb 15;64(4):1411-8 [14973076.001]

[Cites] Magn Reson Imaging. 2004 Jul;22(6):843-50 [15234453.001]

[Cites] Mod Pathol. 2005 Apr;18(4):469-74 [15529179.001]

[Cites] J Nucl Med. 2005 Jan;46(1):121-9 [15632042.001]

[Cites] Skin Res Technol. 2007 Nov;13(4):463-71 [17908200.001]

[Cites] Dermatology. 2007;215(4):365-72 [17912001.001]

[Cites] Panminerva Med. 2007 Sep;49(3):119-38 [17912148.001]

[Cites] Nucl Med Biol. 2007 Nov;34(8):945-53 [17998097.001]

[Cites] Expert Rev Anticancer Ther. 2007 Dec;7(12):1707-16 [18062745.001]

[Cites] Int J Pharm. 2008 Apr 2;353(1-2):233-42 [18191509.001]

[Cites] Bioconjug Chem. 2008 Feb;19(2):539-47 [18197608.001]

[Cites] Skin Res Technol. 2008 Feb;14(1):18-25 [18211598.001]

[Cites] Skin Res Technol. 2008 Feb;14(1):89-92 [18211606.001]

[Cites] Br J Dermatol. 2008 Feb;158(2):329-33 [18215250.001]

[Cites] Dermatol Surg. 2008 May;34(5):610-9 [18261097.001]

[Cites] Anal Sci. 2008 Feb;24(2):185-92 [18270407.001]

[Cites] Curr Opin Oncol. 2008 Mar;20(2):196-200 [18300770.001]

[Cites] Int J Cosmet Sci. 2008 Feb;30(1):1-17 [18377626.001]

[Cites] J Eur Acad Dermatol Venereol. 2008 May;22(5):606-15 [18410618.001]

[Cites] J Nucl Med. 2008 May;49(5):823-9 [18413404.001]

[Cites] Clin Nucl Med. 2008 May;33(5):353-5 [18431156.001]

[Cites] J Nucl Med. 2008 Jun;49(6):879-86 [18483090.001]

[Cites] Semin Cutan Med Surg. 2008 Mar;27(1):37-43 [18486023.001]

[Cites] AJR Am J Roentgenol. 2008 Jul;191(1):285-9 [18562760.001]

[Cites] Cancer Res. 1990 Feb 1;50(3 Suppl):904s-908s [2297740.001]

[Cites] Cancer Res. 1990 Feb 1;50(3 Suppl):941s-948s [2297746.001]

[Cites] Cancer Res. 1990 Jun 1;50(11):3445-52 [2334941.001]

[Cites] Neoplasma. 1989;36(5):505-11 [2812147.001]

[Cites] J Nucl Med. 1988 Mar;29(3):329-37 [3346743.001]

[Cites] Biomed Pharmacother. 1986;40(10):392-8 [3580508.001]

[Cites] Cancer Immunol Immunother. 1987;24(3):221-4 [3594484.001]

[Cites] NCI Monogr. 1987;(3):3-9 [3821916.001]

[Cites] Radiology. 1985 May;155(2):487-92 [3983400.001]

[Cites] Cancer Res. 1985 Jul;45(7):3378-87 [4005860.001]

[Cites] Br J Urol. 1994 Oct;74(4):521-2 [7820438.001]

[Cites] Arch Dermatol. 1995 Mar;131(3):279-85 [7887656.001]

[Cites] Int J Cancer. 1994 Sep 1;58(5):749-55 [8077062.001]

[Cites] Melanoma Res. 1993 Dec;3(6):395-401 [8161879.001]

[Cites] Br J Dermatol. 1993 May;128(5):525-32 [8504043.001]

[Cites] Clin Nucl Med. 1997 Jan;22(1):25-9 [8993869.001]

[Cites] Nucl Med Biol. 1997 Feb;24(2):171-8 [9089709.001]

[Cites] Bioconjug Chem. 1997 May-Jun;8(3):347-53 [9177840.001]

[Cites] Magn Reson Med. 2005 Mar;53(3):621-7 [15723405.001]

[Cites] PLoS Med. 2005 Mar;2(3):e70 [15783258.001]

[Cites] Mol Imaging. 2004 Oct;3(4):343-51 [15802051.001]

[Cites] J Med Chem. 2005 Apr 21;48(8):2985-92 [15828837.001]

[Cites] J Nucl Med. 2005 Aug;46(8):1333-41 [16085591.001]

[Cites] Nat Med. 2005 Nov;11(11):1250-5 [16258537.001]

[Cites] Mod Pathol. 2006 Feb;19 Suppl 2:S127-47 [16446711.001]

[Cites] J Am Acad Dermatol. 2006 Apr;54(4):638-43 [16546585.001]

[Cites] J Nucl Med. 2006 May;47(5):763-9 [16644745.001]

[Cites] J Nucl Med. 2006 Jun;47(6):957-67 [16741305.001]

[Cites] Clin Cancer Res. 2006 Jul 1;12(13):3942-9 [16818691.001]

[Cites] Nat Biotechnol. 2006 Jul;24(7):848-51 [16823374.001]

[Cites] J Nucl Med. 2006 Sep;47(9):1434-9 [16954550.001]

[Cites] Mol Cancer Ther. 2006 Nov;5(11):2624-33 [17121909.001]

[Cites] J Dermatol Sci. 2007 Mar;45(3):167-73 [17215110.001]

[Cites] Conf Proc IEEE Eng Med Biol Soc. 2005;1:190-2 [17282143.001]

[Cites] Melanoma Res. 2007 Apr;17(2):117-27 [17496787.001]

[Cites] Tech Vasc Interv Radiol. 2006 Sep;9(3):125-32 [17561215.001]

[Cites] Arch Dermatol. 2007 Jun;143(6):727-34 [17576938.001]

[Cites] J Dtsch Dermatol Ges. 2007 Aug;5(8):689-707 [17659044.001]

[Cites] Int J Dermatol. 2007 Sep;46(9):895-904 [17822489.001]

[Cites] Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):186-208 [17846765.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17489-93 [17954911.001]

[Cites] Expert Rev Anticancer Ther. 2007 Nov;7(11):1633-42 [18020929.001]

[Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:56-8 [18067634.001]

[Cites] Mol Cancer Ther. 2008 Jan;7(1):101-9 [18202013.001]

[Cites] Cancer. 2002 Feb 15;94(4 Suppl):1196-201 [11877745.001]

[Cites] Phys Med Biol. 2002 Apr 7;47(7):R67-84 [11996068.001]

[Cites] J Med Chem. 2002 Jul 4;45(14):3048-56 [12086490.001]

[Cites] Ann Surg Oncol. 2002 Aug;9(7):646-53 [12167578.001]

[Cites] Phys Med Biol. 2002 Nov 7;47(21):3847-52 [12452576.001]

[Cites] J Nucl Med. 2002 Dec;43(12):1699-706 [12468522.001]

[Cites] J Invest Dermatol. 2003 Jan;120(1):72-8 [12535200.001]

[Cites] J Nucl Med. 2003 Aug;44(8):1210-8 [12902409.001]

[Cites] Cancer Res. 1992 May 1;52(9):2545-8 [1314697.001]

[Cites] Science. 1992 Aug 28;257(5074):1248-51 [1325670.001]

[Cites] Br J Dermatol. 2003 Nov;149(5):1035-40 [14632811.001]

[Cites] Optometry. 2003 Dec;74(12):760-4 [14677727.001]

[Cites] Klin Monbl Augenheilkd. 2003 Dec;220(12):822-9 [14704937.001]

[Cites] J Nucl Med. 2004 Jan;45(1):116-23 [14734683.001]

[Cites] Nuklearmedizin. 2004 Feb;43(1):26-32 [14978538.001]

[Cites] Br J Dermatol. 2004 Apr;150(4):677-86 [15099363.001]

[Cites] Ann Surg Oncol. 2004 Aug;11(8):731-8 [15249335.001]

[Cites] J Nucl Med. 2004 Aug;45(8):1323-7 [15299056.001]

[Cites] J Invest Dermatol. 2004 Sep;123(3):458-63 [15304083.001]

[Cites] Br J Dermatol. 2004 Aug;151(2):424-32 [15327550.001]

[Cites] Cancer J. 2004 Jul-Aug;10(4):262-70 [15383207.001]

[Cites] Vestn Rentgenol Radiol. 2004 Mar-Apr;(2):44-54 [15458273.001]

[Cites] Photodermatol Photoimmunol Photomed. 2004 Dec;20(6):283-8 [15533235.001]

[Cites] Phys Med Biol. 2004 Nov 7;49(21):N363-9 [15584535.001]

[Cites] Arch Dermatol. 2005 Feb;141(2):217-24 [15724019.001]

[Cites] Arch Dermatol. 2005 Feb;141(2):269-70 [15724029.001]

[Cites] Curr Opin Oncol. 2005 Mar;17(2):154-9 [15725921.001]

[Cites] J Nucl Med. 2005 May;46(5):887-95 [15872364.001]

[Cites] Curr Opin Oncol. 1992 Apr;4(2):380-5 [1591311.001]

[Cites] Nucl Med Biol. 2005 Jul;32(5):485-93 [15982579.001]

[Cites] Cancer Metastasis Rev. 2005 Jun;24(2):195-222 [15986132.001]

[Cites] Clin Cancer Res. 2005 Aug 1;11(15):5616-21 [16061880.001]

[Cites] J Dermatol Sci. 2005 Nov;40(2):85-94 [16139481.001]

[Cites] Radiology. 1992 Aug;184(2):427-34 [1620841.001]

[Cites] J Biomed Opt. 2005 Sep-Oct;10(5):054010 [16292970.001]

[Cites] J Am Acad Dermatol. 2005 Dec;53(6):979-85 [16310058.001]

[Cites] Arch Dermatol. 2006 Mar;142(3):393; author reply 393 [16549724.001]

[Cites] Cancer. 2006 Jul 1;107(1):193-200 [16615102.001]

(PMID = 21437135.001).

[ISSN] 1178-7015

[Journal-full-title] Clinical, cosmetic and investigational dermatology

[ISO-abbreviation] Clin Cosmet Investig Dermatol

[Language] eng

[Publication-type] Journal Article

[Publication-country] New Zealand

[Other-IDs] NLM/ PMC3048596

[Keywords] NOTNLM ; anatomical imaging / antibody / melanoma / molecular imaging / positron emission tomography / skin cancer